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Intellectual disability is characterized by a total IQ below 70, significant impairments 
in cognitive and adaptive skills, and onset before 18 years of age (DSM-IV 1999). 
Intellectual disability is not one specific condition with one specific etiology, but an 
umbrella diagnosis for over thousand disorders and diseases. Many of these specific 
disorders or diseases have a specific phenotype, both physical and behavioural. 
Although individuals with intellectual disability can have the same illnesses as 
typically developing individuals, several health problems, such as sleep problems, 
are more prevalent in individuals with intellectual disability than in their peers. 
We established an outpatient clinic for the treatment of sleep problems in 
individuals with intellectual disability, not only because of the treatment of severe 
sleep problems in the individuals involved, but also to enhance the empirical 
knowledge regarding the assessment and treatment of sleep problems in this 
target group. this thesis reflects our clinical and scientific endeavors in this area.
sleep probleMs in individuals with intellectual 
disabilities
Sleep problems are a common complaint in primary care, with prevalence rates 
ranging from 10% to 40% (Simon & VonKorff 1997; Sateia et al. 2000) in adults and 
from 30% to 41% in children (Lipton et al. 2008). Prevalence rates for individuals 
with intellectual disability range from 13% to 88%, depending on study design, 
participant characteristics and definition of sleep problems. In some syndromes, 
such as Angelman syndrome, fragile X syndrome, Rett syndrome, Smith Magenis 
syndrome and tuberous sclerosis, the prevalence rate of sleep problems is 
exceptionally high (O’Callaghan et al. 1999; Edelman et al. 2007; Young et al. 2007; 
Pelc et al. 2008; Kronk et al. 2009).
the most common types of sleep problems in individuals with intellectual 
disability are problems with falling asleep and sleep maintenance (Bartlett et al. 
1985; Quine 1991). Sleep problems, especially insomnia, can have a serious negative 
influence on daytime functioning of the person with intellectual disability. It can 
cause somnolence, lethargy, and diminished functioning, as well as irritability, 
hyperactivity and behavioural problems (Quine 1991; Wiggs & Stores 1996; Chadwick 
et al. 2000; Didden et al. 2002). Sleep problems also have adverse consequences for 
the well-being of the individual’s caregivers (see e.g. Didden et al. 2002).
treatMent of sleep probleMs
treatment of sleep problems in individuals with intellectual disability may take the 
form of at least three strategies, namely a bedtime routine (good sleep hygiene), 
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behavioural strategies, and pharmacological strategies (Lancioni et al. 1999). 
Professionals should however be careful about prescribing drugs to individuals 
with intellectual disability, because they often take other medications and the risk of 
drug interactions is then increased. this interaction may result in daytime sedation, 
increased risk of sleep related breathing disorder and behavioural problems (Dodge & 
Wilson 2001; Doran et al. 2006). In some cases, hypnotics even can lead to paradoxical 
reactions such as hyperactivity and agitation (Kalachnik et al. 2002). therefore, 
effective sleep medication that does not have these adverse side-effects is needed. 
Melatonin 
A number of study trials indicate that melatonin is effective in the treatment of 
insomnia (McArthur & Budden 1998; O’Callaghan et al. 1999; Hätönen et al. 
1999; Dodge & Wilson 2001; Niederhofer et al. 2003; Coppola et al. 2004; Garstang 
& Wallis 2006; Laakso et al. 2007; Wasdell et al. 2008). Several reviews of these 
trials emphasized the benefits of melatonin in the treatment of sleep problems in 
individuals with intellectual disability (turk 2003; Jan & Freeman 2004; Phillips & 
Appleton 2004; Wassmer & Whitehouse 2006; Sajith & Clarke 2007). Despite positive 
results reported in these studies in individuals with intellectual disability, there 
still is debate about the efficacy of melatonin in general, given the mixed outcomes 
of a recent publication of two meta-analyses that included studies performed in 
individuals without intellectual disability (Brzezinski et al. 2005; Buscemi et al. 
2005) and one meta-analysis (Buscemi et al. 2006) in which 6 out of 11 studies were 
performed in individuals with intellectual disability.
there are several anecdotal reports suggesting that in persons with intellectual 
disability melatonin treatment may also reduce daytime behavioural problems (Jan 
et al. 1994; Jan 2000; Ivanenko et al. 2003; Jan & Freeman 2004; Coppola et al. 2004; 
Carr et al. 2007).
Melatonin causes few side-effects and it is considered safe on long term in the 
treatment of chronic insomnia in individuals with intellectual disability (Jan 2000; 
Ivanenko 2003; Buscemi et al. 2006; Carr et al. 2007). However, there are several case 
reports suggesting that in a number of individuals melatonin may lose its effectiveness 
during long term use (McArthur & Budden 1998; Ishizaki et al.1999; Jan et al. 2000; 
Andersen et al. 2008). tolerance to melatonin was suggested as a probable cause of 
the disappearing effectiveness of exogenous melatonin (Jan et al. 2000).
research questions and thesis outline
In this thesis, results are presented of studies on (a) efficacy of melatonin in 
the treatment of sleep problems in individuals with intellectual disability, 
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(b) its effects on daytime challenging behaviours, and (c) a possible cause of 
disappearing effectiveness of melatonin. these studies aim to provide an answer 
to the following five main research questions. these are:
1.  Is melatonin effective in the treatment of chronic insomnia in persons 
with intellectual disabilities?
2.  Does melatonin reduce sleep problems in persons with intellectual 
disability?
3.  Does melatonin reduce sleep problems in persons with Angelman 
syndrome?
4.  Does melatonin reduce co-existing daytime challenging behaviour?
5.  What may be the cause of the loss of response to melatonin in patients 
after an initial successful treatment? 
exogenous Melatonin for sleep probleMs in individuals 
with intellectual disability: a Meta-analysis
While a number of trials indicate that melatonin is effective in the treatment of 
insomnia in individuals with intellectual disability (McArthur & Budden 1998; 
O’Callaghan et al. 1999; Hätönen et al. 1999; Dodge & Wilson 2001; Niederhofer et 
al. 2003; Coppola et al. 2004; Garstang & Wallis 2006; Laakso et al. 2007; Wasdell 
et al. 2008), three meta-analyses on melatonin (Brzezinski et al. 2005; Buscemi et 
al. 2005; Buscemi et al. 2006) in predominantly non-disabled individuals raised 
doubts on the efficacy of melatonin. At the time of this study, it was unclear 
whether melatonin was or was not effective for reducing sleep problems in 
individuals with intellectual disability. therefore, we investigated the efficacy 
of melatonin in the management of sleep problems in persons with intellectual 
disability by performing a meta-analysis of placebo controlled randomized trials 
with melatonin. Results of this study are presented in chapter 2 of this thesis. 
Melatonin treatMent in individuals with intellectual 
disability and chronic insoMnia: a randoMized 
placebo-controlled study
Until recently, only few randomized trials with melatonin in persons with 
intellectual disability have been conducted (Camfield et al. 1996; McArthur & 
Budden, 1998; O’Callaghan et al. 1999; Dodge & Wilson 2001; Niederhofer 2003; 
Coppola et al. 2004; Garstang & Wallis, 2006; Laakso et al. 2007; Wasdell et al. 
2008). Conclusions drawn in these studies were based on small sample sizes, 
Dim Light Melatonin Onset (DLMO) was not measured, and the influence of 
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exogenous melatonin on the endogenous melatonin rhythm was not studied. 
therefore, we conducted a randomized double-blind placebo-controlled trial 
in a relatively large sample of individuals with intellectual disability (n = 51) to 
investigate the effectiveness of exogenous melatonin in persons with intellectual 
disability who had chronic insomnia. Next to this, we measured DLMO and 
assessed the influence of exogenous melatonin on the endogenous melatonin 
rhythm. the results of this study are presented in chapter 3 of the thesis. 
In our three studies, we used a parallel study design, because a cross-over 
design with intra-individual comparison of melatonin and placebo is inappropriate 
when evaluating the efficacy of melatonin (see chapter 7). Exogenous melatonin 
can cause a phase shift advance of the endogenous melatonin rhythm and this 
effect can last for several days or weeks after treatment has stopped. therefore, 
participants who receive melatonin in the first phase of the study may experience 
a carry-over effect of the melatonin phase into the placebo phase (Kunz et al. 2004; 
Laakso et al. 2007). By consequence, carry-over effects can result in a smaller 
difference in outcome between the melatonin and placebo phase of the study, 
and therefore carry-over effects may be responsible for not finding a significant 
difference in the dependent variable(s) between melatonin and placebo. 
Melatonin for chronic insoMnia in angelMan 
syndroMe: a randoMized placebo-controlled trial
Prevalence of sleep problems in Angelman syndrome have been reported up to 
90% (Clayton Smith et al. 1993; Bruni et al. 2004; Didden et al. 2004). Because 
of this high prevalence, sleep problems are listed as ‘associated features’ in the 
clinical diagnostic criteria for Angelman syndrome (Williams et al. 2006).
Sleep problems in children with Angelman syndrome consist of problems 
with settling, falling asleep, frequent night wakings and difficulty to fall asleep 
after waking. In many cases, these sleep problems appear resistant to behavioural 
therapy as well as conventional sleep medication.
A striking finding was reported by Zhdanova et al. (1999) who studied sleep 
problems in an open-label study in 13 children with Angelman syndrome 
and chronic insomnia, and who found very low melatonin levels at baseline. 
A relatively low dose of melatonin (i.e. 0.3 mg) significantly decreased sleep 
latency and increased total sleep time in these children. the most important 
shortcoming of this study was that it lacked a placebo controlled double blind 
design. therefore, we examined the efficacy of melatonin on chronic sleep 
problems in 8 individuals with Angelman syndrome and data were collected 
within a randomized double-blind placebo-controlled trial. the results of this 
study are reported in chapter 4.
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Melatonin decreases daytiMe challenging behaviour 
in persons with intellectual disability and chronic 
insoMnia
Persons with intellectual disability and sleep problems exhibit more daytime 
challenging behaviours, irritability and lethargy than persons with intellectual 
disability who do not have sleep problems (Wiggs & Stores, 1996; Chadwick et 
al. 2000; Didden et al. 2002). there are several anecdotal reports suggesting that 
in persons with intellectual disability and sleep problems, melatonin is not only 
an effective treatment for sleep problems, it also is associated with a reduction 
in daytime behavioural problems (Jan et al. 1994; Jan 2000; Ivanenko et al. 2003; 
Jan & Freeman, 2004; Coppola et al. 2004; Carr et al. 2007). In these studies, no 
correlations between a reduction of sleep problems and behavioural problems 
were given. Furthermore, no attempt was made to explain the reduction in 
daytime challenging behaviour, or the reduction in challenging behaviour was 
attributed to the improvement of sleep itself, without further specification. 
to investigate the relationship between the effectiveness of melatonin on 
sleep problems and concordant change in daytime challenging behaviours, 
we investigated the effects of melatonin on daytime challenging behaviour in 
a randomized placebo-controlled trial. In this trial, we explored whether there 
were significant associations between daytime challenging behaviour, chronic 
insomnia and melatonin circadian rhythm. Results of this study are presented 
in chapter 5.
loss of response to Melatonin treatMent is associated 
with slow Melatonin MetabolisM
In our study in children with Angelman syndrome, some parents reported 
the return of night waking after 4 weeks of treatment (see chapter 4). In these 
patients, salivary melatonin levels after 4 weeks of treatment were extremely 
high (>50 pg/ml), when they had been very low at baseline. In these patients 
sleep improved again substantially after the melatonin dose was lowered to 0.1 
mg. We postulated that these patients, although showing the clinical picture of 
melatonin tolerance, in fact were CYP1A2 poor metabolizers.
Surprisingly, in the medical scientific literature no attention so far has been 
paid to the phenomenon of the loss of response to melatonin. Only a small 
number of case reports suggest that melatonin can lose its effectiveness during 
long term use (McArthur & Budden1998; Ishizaki et al.1999; Jan et al. 2000; 
Andersen et al. 2008). In these studies, possible causes of the loss of response to 
melatonin were not explored. tolerance to melatonin was suggested as a probable 
cause (Jan et al. 2000).
INtRODUCtION
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We performed a pilot study on melatonin metabolism in patients in whom 
the initial effectiveness of melatonin disappeared, in order to test our hypothesis 
that loss of response to exogenous melatonin is due to 24 hour high melatonin 
levels, which is caused by slow melatonin metabolism. Results of this study are 
presented in the 6th chapter of this thesis.
In the 7th chapter of this thesis implications of the results are discussed. A 
summary completes this thesis. 
references
American Psychiatric Association. (1994) Diagnostic and Statistical Manual 
of Mental Disorders, 4th edn. Washington: DC. American Psychiatric 
Association.
Andersen I.M., Kaczmarska J., McGrew S.G., & Malow B.A. (2008) Melatonin 
for insomnia in children with autism spectrum disorders. Journal of Child 
Neurology 23, 482-5.
Bartlett L.B., Rooney V., & Spedding S. (1985). Nocturnal difficulties in a population 
of mentally handicapped children. British Journal of Mental Subnormality 31, 
54–9.
Bruni O., Ferri R., D’Agostino G., Miano S., Roccella M., & Elia M. (2004) 
Sleep disturbances in Angelman syndrome: a questionnaire study. Brain & 
Development 26, 233-40.
Brzezinski A., Vangel M.G., Wurtman R.J., Norrie G., Zhdanova I., Ben-Shushan 
A., & Ford I. (2005) Effects of exogenous melatonin on sleep: a meta-analysis. 
Sleep Medicine Reviews 9, 41-50.
Buscemi N., Vandermeer B., Hooton N., Pandya R., tjosvold L., Hartling L., 
Baker G., Klassen t.P., & Vohra S. (2005) the efficacy and safety of exogenous 
melatonin for primary sleep disorders. A meta-analysis. Journal of General 
Internal Medicine 20, 1151-8.
Buscemi N., Vandermeer B., Hooton N., Pandya R., tjosvold L., Hartling L., 
Vohra S., Klassen t.P., & Baker G. (2006) Efficacy and safety of exogenous 
melatonin for secondary sleep disorders and sleep disorders accompanying 
sleep restriction: meta-analysis. British Medical Journal 332, 385-93.
Camfield P., Gordon K., Dooley J., & Camfield C. (1996) Melatonin appears 
ineffective in children with intellectual deficits and fragmented sleep: six ‘N of 
1’ trials. Journal of Child Neurology 11, 341–3.
Carr R., Wasdell M.B., Hamilton D., Weiss M.D., Freeman R.D., tai J., Rietveld 
W., & Jan J.E. (2007) Long-term effectiveness of melatonin therapy in children 
with treatment-resistant circadian rhythm sleep disorders. Journal of Pineal 
CHAPtER 1
15
Research 43, 351-9.
Chadwick O., Piroth N., Walker J., Bernard S., & taylor E. (2000) Factors affecting 
the risk of behaviour problems in children with severe intellectual disability. 
Journal of Intellectual Disability Research 44, 108–23.
Clayton-Smith J. (1993) Clinical research on Angelman syndrome in the United 
Kingdom: observations on 82 affected individuals. American Journal of Medical 
Genetics 46, 12-5.
Coppola G., Iervolino G., Mastrosimone M., La torre G., Ruiu F., & Pascotto A. 
(2004) Melatonin in wake-sleep disorders in children, adolescents and young 
adults with mental retardation with or without epilepsy: a double-blind, cross-
over, placebo-controlled trial. Brain & Development 26, 373-6.
Didden R., Korzilius H., Van Aperlo B., Van Overloop C., & De Vries M. (2002) 
Sleep problems and daytime problem behaviours in children with intellectual 
disability. Journal of Intellectual Disability Research 46, 537-47.
Didden R., Korzilius H., Smits M.G., & Curfs L. M. G. (2004) Sleep problems in 
individuals with Angelman syndrome. American Journal of Mental Retardation 
109, 275-84.
Dodge N. N., & Wilson G. A. (2001) Melatonin for treatment of sleep disorders in 
children with developmental disabilities. Journal of Child Neurology 16, 581–4.
Doran S., Harvey M., & Horner R. (2006) Sleep and developmental disabilities: 
assessment, treatment, and outcome measures. Mental Retardation 44, 13–27.
Edelman E. A., Girirajan S., Finucane B., Patel P. I., Lupski J. R., Smith A. C., 
& Elsea S. H. (2007) Gender, genotype, and phenotype differences in Smith-
Magenis syndrome: a meta-analysis of 105 cases. Clinical Genetics 71, 540-50.
Garstang J., & Wallis M. (2006) Randomized controlled trial of melatonin for 
children with autistic spectrum disorders and sleep problems. Child: Care, 
Health and Development 32, 585–9.
Hätönen t., Kirveskari E., Heiskala H., Sainio K., Laakso M. L., & Santavuori 
P. (1999) Melatonin ineffective in neuronal ceroid lipofuscinosis patients with 
fragmented or normal motor activity rhythms recorded by wrist actigraphy. 
Molecular Genetics and Metabolism 66, 401-6.
Ishizaki A., Sugama M., & takeuchi N. (1999) [Usefulness of melatonin for 
developmental sleep and emotional/behavior disorders. Studies of melatonin 
trial on 50 patients with developmental disorders] [Article in Japanese] No To 
Hattatsu 31, 428-37.
Ivanenko A., McLaughlin Crabtree V., tauman R., & Gozal D. (2003) Melatonin 
in children and adolescents with insomnia: a retrospective study. Clinical 
Pediatrics 42, 51-8.
Jan M. M. S. (2000) Melatonin for the treatment of handicapped children with 
severe sleep disorders. Pediatric Neurology 23, 229–32.
INtRODUCtION
16
Jan J. E., Espezel H., & Appleton R. E. (1994) the treatment of sleep disorders 
with melatonin. Developmental Medicine & Child Neurology 36, 97–107.
Jan J. E., Hamilton D., Seward N., Fast D. K., Freeman R. D., & Laudon M. (2000) 
Clinical trials of controlled-release melatonin in children with sleep-wake cycle 
disorders. Journal of Pineal Research 29, 34-9.
Jan J.E., & Freeman R.D. (2004) Melatonin therapy for circadian rhythm sleep 
disorders in children with multiple disabilities: what have we learned in the last 
decade? Developmental Medicine & Child Neurology 46, 776–82.
Kalachnik J. E., Hanzel t. E., Sevenich R., & Harder S. R. (2002) Benzodiazepine 
behavioral side effects: review and implications for individuals with mental 
retardation. American Journal of Mental Retardation 107, 376-410.
Kronk R., Dahl R., & Noll R. (2009) Caregiver reports of sleep problems on a 
convenience sample of children with Fragile X syndrome. American Journal on 
Intellectual and Developmental Disabilities 114, 383-92.
Kunz D., Mahlberg R., Müller C., tilmann A., & Bes F. (2004) Melatonin in 
patients with reduced REM sleep duration: two randomized trials. The Journal 
of Clinical Endocrinology & Metabolism 89, 128–34.
Laakso M. L., Lindblom N., Leinonen L., & Kaski M. (2007) Endogenous melatonin 
predicts efficacy of exogenous melatonin in consolidation of fragmented wrist-
activity rhythm of adult patients with developmental brain disorders: a double-
blind, placebo-controlled, crossover study. Sleep Medicine 8, 222-39.
Lancioni G. E., O’Reilly M. F., & Basili G. (1999) Review of strategies for treating 
sleep problems in persons with severe or profound mental retardation or 
multiple handicaps. American Journal of Mental Retardation 104, 170-86.
Lipton J., Becker R. E., & Kothare S. V. (2008) Insomnia in childhood. Current 
Opinion in Pediatrics 20, 641–9.
McArthur A. J., & Budden S. S. (1998) Sleep dysfunction in Rett syndrome: a trial 
of exogenous melatonin treatment. Developmental medicine and child neurology 
40, 186-92.
Niederhofer H., Staffen W., Mair A., & Pittschieler K. (2003) Brief report: Melatonin 
facilitates sleep in individuals with mental retardation and insomnia. Journal of 
Autism and Developmental Disorders 33, 469-72.
O’Callaghan F.J., Clarke A.A., Hancock E., Hunt A., & Osborne J.P. (1999) Use of 
melatonin to treat sleep disorders in tuberous sclerosis. Developmental Medicine 
& Child Neurology 41, 123-6.
Pelc K., Cheron G., Boyd S.G., & Dan B. (2008) Are there distinctive sleep problems 
in Angelman syndrome? Sleep Medicine 9, 434-41.
Phillips L., & Appleton R.E. (2004) Systematic review of melatonin treatment 
in children with neurodevelopmental disabilities and sleep impairment. 
Developmental Medicine & Child Neurology 46, 771-5.
CHAPtER 1
17
Quine L. (1991) Sleep problems in children with mental handicap. Journal of 
Mental Deficiency Research 35, 269–90.
Sajith S. G., & Clarke D. (2007) Melatonin and sleep disorders associated with 
intellectual disability: a clinical review. Journal of Intellectual Disability Research 
51, 2-13.
Sateia M. J., Doghramji K., Hauri P. J., & Morin C. M. (2000) Evaluation of Chronic 
Insomnia. Sleep 23, 243-308.
Simon G. E., & VonKorff M. (1997) Prevalence, Burden, and treatment of 
Insomnia in Primary Care. American Journal of Psychiatry 154, 1417–23.
turk J. (2003) Melatonin supplementation for severe and intractable sleep 
disturbance in young people with genetically determined developmental 
disabilities: short review and commentary. Journal of Medical Genetics 11, 793–
96.
Wasdell M. B., Jan J. E., Bomben M. M., Freeman R. D., Rietveld W. J., tai J., 
Hamilton D., & Weiss M.D. (2008) A randomized, placebo-controlled trial of 
controlled release melatonin treatment of delayed sleep phase syndrome and 
impaired sleep maintenance in children with neurodevelopmental disabilities. 
Journal of Pineal Research 44, 57–64.
Wassmer E., & Whitehouse W. P. (2006) Melatonin and sleep in children with 
neurodevelopmental disabilities and sleep disorders. Current Pediatrics 16, 132-
8.
Wiggs L., & Stores G. (1996) Severe sleep disturbance and daytime challenging 
behaviour in children with severe learning disabilities. Journal of Intellectual 
Disability Research 40, 518–28.
Williams C.A., Beaudet A.L., Clayton-Smith J., Knoll J.H., Kyllerman M., Laan 
L.A., Magenis R.E., Moncla A., Schinzel A.A., Summers J.A., & Wagstaff J. 
(2006) Angelman syndrome 2005: updated consensus for diagnostic criteria. 
American Journal of Medical Genetics. Part A 140, 413-8.
Young D., Nagarajan L., De Klerk N., Jacoby P., Ellaway C., & Leonard H. (2007) 
Sleep problems in Rett syndrome. Brain & Development 29, 609-16.
Zhdanova I. V., Wurtman R. J., & Wagstaff J. (1999) Effects of low dose of 
melatonin on sleep in children with Angelman syndrome. Journal of Pediatric 
Endocrinology & Metabolism 12, 57–67.
INtRODUCtION
18
19
chapter 2 
EXOGENOUS MELAtONIN FOR SLEEP PROBLEMS 
IN INDIVIDUALS WItH INtELLECtUAL DISABILItY: 
A MEtA-ANALYSIS
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(2009) Exogenous melatonin for sleep problems in individuals with intellectual 
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abstract
Background Recent meta-analyses on melatonin has raised doubts as to whether 
melatonin is effective in treating sleep problems in people without intellectual 
disabilities. this is in contrast to results of several trials on melatonin in treating 
sleep problems in individuals with intellectual disabilities. 
Methods to investigate the efficacy of melatonin in treating sleep problems 
in individuals with intellectual disabilities, we performed a meta-analysis 
of placebo-controlled randomized trials of melatonin in individuals with 
intellectual disabilities and sleep problems. Data were selected from articles 
published on PubMed, Medline, and Embase between January 1990 and July 
2008. We examined the influence of melatonin on sleep latency, total sleep 
time, and number of wakes per night. Quality of trials was assessed using the 
Downs and Black checklist. 
Results Nine studies (including a total of 183 individuals with intellectual 
disabilities) showed that melatonin treatment decreased sleep latency by 
a mean of 34 minutes (p<0.001), increased total sleep time by a mean of 50 
minutes (p<0.001), and significantly decreased the number of wakes per night 
(p<0.05). 
Conclusions Melatonin decreases sleep latency and number of wakes per night, 
and increases total sleep time in individuals with intellectual disabilities.
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introduction
Sleep problems are reported to occur in 13 to 86% of individuals with intellectual 
disabilities depending on study design, participant characteristics, and definition 
of sleep problems (Didden et al. 2002). Such problems are often complex and 
usually more difficult to treat than in individuals without intellectual disability. 
When behavioural treatment for the sleep problems (Wiggs & Stores 1998; 
Montgomery et al. 2004) is ineffective, sedatives are often prescribed. However, 
sedatives may induce serious side effects (Doran et al. 2006), such as daytime 
sedation, increased risk of sleep related breathing problems, and behavioural 
problems. Where individuals with intellectual disabilities take other medications, 
the risk of drug interactions is increased. therefore, melatonin may be an effective 
and safe treatment option for sleep problems in individuals with intellectual 
disabilities. 
Melatonin, a hormone released by the pineal gland during darkness, is 
a chronobiotic drug with hypnotic properties (Wirz-Justice & Armstrong 
1996). Melatonin secretion is regulated by an endogenous pacemaker in the 
suprachiasmatic nucleus of the hypothalamus (biological clock). Information 
on the light ⁄ dark cycle through the retino-hypothalamic tract is needed to 
synchronize the circadian melatonin rhythm to 24 hours. Many pathophysiological 
conditions can disturb this complex regulatory system and cause dysfunction of 
the sleep– wake system (Claustrat et al. 2005). 
Biological clock disturbances frequently occur in individuals with intellectual 
disability and consequently cause sleep-wake disturbances (Jan & Freeman 
2004; Sajith & Clarke 2007). Low nocturnal melatonin levels have been found, 
for example, in Angelman syndrome, autism, and Rett syndrome. Recently an 
abnormal melatonin synthesis in autism spectrum disorders was discovered 
(Melke et al. 2007).
Several placebo-controlled randomized trials with melatonin in individuals 
with intellectual disabilities have shown that melatonin improves sleep (McArthur 
& Budden 1998; O’Callaghan et al. 1999; Hätönen et al. 1999; Dodge & Wilson 
2001; Niederhofer et al. 2003; Coppola et al. 2004; Garstang & Wallis 2006; Laakso 
et al. 2007; Wasdell et al. 2008), i.e. induces a significant reduction of sleep latency 
and an increase in total sleep time. Several reviews based on these trials, as well 
as on open studies and case reports, emphasize the benefits of melatonin in the 
treatment of sleep problems in individuals with intellectual disabilities (Sajith 
& Clarke 2007; Wassmer & Whitehouse 2006; Jan & Freeman 2004; Phillips & 
Appleton 2004; turk 2003). these results, however, are not in line with results 
of three meta-analyses of individuals with sleep problems without intellectual 
disabilities (Brzezinski et al. 2005; Buscemi et al. 2005; Buscemi et al. 2006). 
Although the meta-analysis by Brzezinski et al. (2005) showed a statistically 
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significant improvement of sleep latency, sleep efficiency, and total sleep time, 
differences between the melatonin and placebo groups were small and seem to 
be of minor clinical importance.
In the first meta-analysis by Buscemi et al. (2005) on the efficacy of melatonin 
in the treatment of primary sleep disorders, evidence was found that melatonin 
is not effective in treating most primary sleep disorders, except for the treatment 
of delayed sleep phase syndrome. In the second meta-analysis by Buscemi et al. 
(2006) no evidence for the effectiveness of melatonin in treating secondary sleep 
disorders was found. these results suggest that melatonin is not effective in 
individuals without intellectual disability. As stated above, this is in stark contrast 
to outcomes of controlled trials in individuals with intellectual disability. At 
present, no quantitative review has been published on the outcomes of placebo-
controlled trials on the efficacy of melatonin in individuals with intellectual 
disabilities. therefore, we investigated the efficacy of melatonin in the treatment 
of sleep problems in persons with intellectual disabilities, by performing a meta-
analysis of placebo-controlled, randomized trials on melatonin in individuals 
with sleep problems and intellectual disabilities.
Method
Search strategy
We performed a computerized search in the electronic databases PubMed, 
Medline, and Embase for trials on melatonin in individuals with sleep problems 
and intellectual disabilities, published between January 1990 and July 2008. Search 
terms used were, ‘melatonin’ and terms used to describe intellectual disabilities 
(i.e. ‘developmental disability’, ‘intellectual disability’, ‘learning disorder’, ‘mental 
retardation’, and ‘neurodevelopmental disability’). In addition, a hand search was 
undertaken of reference lists of articles identified through this search. 
Selection 
All studies in which melatonin was used as an intervention in treating sleep 
problems in individuals with intellectual disability were initially selected and 
reviewed. Studies for the meta-analysis were included if (1) they used a randomized 
double-blind placebo-controlled design, (2) included individuals with any type of a 
diagnosis of intellectual disabilities, (3) provided quantitative data on at least one 
of the following primary outcome measures: sleep latency (time between laying 
down to sleep and the onset of sleep), total sleep time and number of wakes per 
night, and (4) results were reported in English. Methodological quality of each 
study was assessed by two independent reviewers using the Downs and Black 
checklist (Downs & Black 1998). 
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Data extraction 
Outcome variables in this study included, sleep latency, number of wakes per 
night, and total sleep time. the number of minutes in the time measurements was 
transformed to decimals. For each study, mean differences and standard deviations 
(SDs) between baseline and treatment were calculated. For this purpose, we used 
Elbourne et al.’s method (2002) to compute SDs of the differences, imputing a 
correlation of 0.5, as these were not available from the studies.
Meta-analysis with Interactive eXplanations (MIX: version 1.4 [Bax et al. 
2006]) was used to perform the calculations. All measures were continuous; as 
association measure, the mean difference was applied. Following Sutton et al. 
(2000), the inverse variance method was used to weigh the number of participants 
in the studies. We used the random effects model; alpha level was 0.05 for each 
outcome. the numerical output consisted of the empirical value, the mean 
difference and 95% confidence interval (CI) of each study together with the z 
score and p value and the weight of the studies. As graphical output, standard 
forest plots were drawn containing mean differences and the 95% CI of each 
study, as well as of the pooled analysis.
In order to assess possible publication bias (Begg & Berlin 1988) we graphically 
inspected funnel plots, a scatter plot of treatment against the inverse standard 
error of each study (Light & Pillemer 1984; Sterne et al. 2001; Bax et al. 2006) and 
calculated the adjusted rank correlation test (Greenland 1994). to test for statistical 
heterogeneity between studies, Galbraith plots (Bax et al. 2006) were inspected 
and the tau-squared statistic, an estimate of the between study variance, was 
calculated (DerSimonian-Laird method in Bax et al. 2006). In order to save space, 
the funnel and Galbraith plots were not added.
results
Included studies
the computerized search strategy initially resulted in 276 references. Figure 1 
shows the steps taken throughout the selection process. Screening these articles 
on selection criteria resulted in eight eligible studies. Reference tracking resulted 
in four additional studies, all involving individuals with intellectual disability and 
a specific etiological diagnosis (e.g. Angelman syndrome [Braam et al. 2008-II], 
autism spectrum disorder [Garstang & Wallis 2006], ceroid lipofuscinosis [Hätönen 
1999], and tuberous sclerosis [O’Callaghan et al. 1999]), and, therefore, not found 
by general terms describing intellectual disability in the initial computerized 
search. From these 12 placebo-controlled trials, two studies were excluded because 
no suitable quantitative data were provided (i.e. Niederhofer et al. 2003; Laakso et 
al. 2007) and one study was excluded because it was single blind, and lacked 
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suitable quantitative data (Hätönen et al. 1999). One trial (Garstang & Wallis 
2006) was conducted on a sample of 11 children with autism spectrum disorder 
in which more than half also had intellectual disability. therefore, we included 
nine studies, of which 7 were crossover (i.e. Camfield et al. 1996; McArthur & 
Budden 1998; O’Callaghan et al. 1999; Dodge & Wilson 2001; Coppola et al. 
2004; Garstang & Wallis 2005; Wasdell et al. 2008) and 2 parallel (Braam et al. 
2008-I; 2008-II), all double-blind and placebo-controlled studies and involving 
183 individuals with sleep problems and intellectual disability, aged between 1 
and 78 years. tables I and II depict their demographic characteristics and study 
designs. All sleep studies were performed in the participants’ home setting. 
Participants received melatonin or placebo each during 2 weeks (O’Callaghan et 
al. 1999, Dodge & Wilson 2001) or 4 weeks (McArthur & Budden 1998; Coppola 
et al. 2004; Garstang & Wallis 2005; Braam et al. 2008-I, 2008-II) separated by a 
1-week washout period. In one study (Wasdell et al. 2008) both study medication 
periods lasted 10 days, separated by a washout period of 3 to 5 days (to allow for 
weekends). In one study (Camfield et al. 1996) for each 2-week interval during the 
10-week trial, participants were randomized to receive placebo or melatonin for 
Computerised searches
PubMed 112
Medline 77
Embase 87
Total 276
Papers retrieved  
and screened 8
   Manual searching:
   additional references
RCT 12
 
    No suitable
   quantitative data
Selected for
meta-analysis 9
 
Figure 1:  Study retrieval and selection. RCT, randomized controlled trial.
3
262 no RCT or duplicate
4
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the first week with the alternate agent for the second week. 
Various doses of melatonin were given. In four studies a fixed dose of 5mg 
melatonin was used (O’Callaghan et al. 1999; Dodge & Wilson 2001; Garstang & 
Wallis 2005; Wasdell et al. 2008). In four studies the melatonin dose was based 
either upon individual weight (ranging from 2.5–7.5 mg, McArthur & Budden 
1998), or age (0.5 [<6y] or 1mg [≥6y] (Camfield et al.1996) respectively 2.5 [<6y] or 5 
mg [≥6y] Braam et al. 2008-I, 2008-II). In one study (Coppola et al. 2004) melatonin 
was initiated at a daily dose of 3mg. Parents were allowed to increase this dose 
in case of inefficacy up to 9mg during the following 2 weeks in increments of 
3mg⁄ week. In only four studies explicit information was given about the type 
of melatonin used. three studies used fast release melatonin (McArthur & 
Budden 1998; Braam et al. 2008-I, 2008-II) and in one study (Wasdell et al. 2008) 
a combination of 1mg fast and 4mg sustained release melatonin was given. 
time of administration of study medication also differed across studies, 
ranging from a fixed time of 6 PM (Camfield et al.1996), 8 PM (Dodge & Wilson 
2001), 7 PM, or 8 PM depending on age (Braam et al. 2008-I, 2008-II) or 1 hour 
before set bedtime (McArthur & Budden 1998) to 20 to 30 minutes before the 
child’s most desirable bedtime (Wasdell et al. 2008), 20 minutes before each 
participant’s usual bedtime (O’Callaghan et al. 1999) or even at bedtime (Coppola 
et al. 2004). In one study, time of administration was not specified (Garstang & 
Wallis 2006). 
Studies differed in terms of the patients examined. In five studies, a 
heterogeneous group of patients with intellectual disabilities with different 
etiologies was included (Camfield et al. 1996; Dodge & Wilson 2001; Coppola et 
al. 2004; Wasdell et al. 2008; Braam et al. 2008-I). Four studies were performed 
in patients with a specified diagnosis, in which sleep problems have a relative 
n
First author M F Mean Range Diagnosis
Camfield et al.  (1996) 6 4 2 7:3 3:0 - 13:0 Mental disability
McArthur & Budden (1998) 9 0 9 10:1 4:0 - 17:0 Rett syndrome
O'Callaghan et al.  (1999) 7 3 4 11 2:0 - 28:0 Tuberous sclerosis
Dodge & Wilson (2001) 20 NS NS 7:5 1:1 - 12:0 Developmental disabilities
Coppola et al.  (2004) 25 16 9 10:6 3:7 - 16:0 Mental retardation / learning disability
Garstang & Wallis (2006) 7 6 1 NS 5:0 - 15:0 Autistic spectrum disorders
Wasdell et al.  2008) 50 31 19 7:5 2:1 - 18:10 Neurodevelopmental disability
Braam et al.  (2008-I) 51 28 23 22:2 2:0 - 78:0 Intellectual disability
Braam et al.  (2008-II) 8 3 5 10:04 4:0 - 20:0 Angelman syndrome
NS, not specified.
Table 1: Characteristics of participants of included studies
Sex Age (y:mo)
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high prevalence. these were, Angelman syndrome (Braam et al. 2008-II), 
autism spectrum disorders (Garstang & Wallis 2006), Rett syndrome (McArthur 
& Budden 1998), and tuberous sclerosis (O’Callaghan et al. 1999). In all nine 
studies, sleep parameters were measured using sleep diaries. In two studies, data 
from actigraphic recordings were available (McArthur & Budden 1998; Wasdell 
et al. 2008). 
Melatonin decreased sleep latency by a mean of 34 minutes (p<0.0001), 
significantly decreased mean number of wakes per night (p=0.024), and increased 
total sleep time by 50 minutes (p<0.0001). Figures 2, 3, and 4 summarize the 
means and SDs for sleep latency, total sleep time, and number of wakes per 
night for melatonin and placebo groups for the trials that provided data on this 
outcome.
the mean quality score on the Downs and Black checklist (Downs & Black 
1998) from the two reviewers of the included studies was 25.28 out of 32 (SD=3.03; 
range 19–31). Intraclass correlation (mean measures, two-way random effects 
model using an absolute agreement definition) between the two reviewers was 
0.90 (p=0.002; 95% CI: 0.59–0.98). 
Graphical examination of the funnel plots showed no substantial effect of 
publication bias. this finding was corroborated by the adjusted rank correlations, 
for sleep latency, 0.19 (p=0.55); total sleep time, 0.00 (p=1); and number of night 
awakenings 0.25 (p=0.39). Publication bias did not substantially affect the results 
of the meta-analyses. 
Inspection of Galbraith plots showed that there was some indication of 
statistical heterogeneity. For sleep latency and total sleep time two studies 
(Garstang & Wallis 2006; Wasdell et al. 2008) had smaller variances than the 
other studies; for number of night awakenings this was the case for one study 
(Garstang & Wallis 2006); however, the tau-squared measure of heterogeneity 
was 0 for all three sleep parameters. As a result we conclude that heterogeneity of 
the studies did not affect the outcomes of the meta-analyses.
Adverse effects
Specified reports on adverse effects were given in four studies (Dodge & Wilson 
2001; Wasdell et al. 2008; Braam et al. 2008-I; Braam et al. 2008-II). Adverse effects 
were minor and their incidence in both melatonin and placebo phases were the 
same. In one study on children with Angelman syndrome (Braam et al. 2008-II), 
parents of one child reported an increase in night wakes in the fourth treatment 
week. two studies reported that no significant adverse side effect was observed 
(McArthur & Budden1998; Coppola et al. 2004), while in another three studies no 
information on side effects was given (O’Callaghan et al. 1999; Garstang & Wallis 
2006; Camfield et al. 1996).
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discussion
this meta-analysis showed that melatonin treatment significantly decreased 
sleep latency, increased total sleep time, and reduced the number of wakes per 
night in individuals with sleep problems and intellectual disability. It confirms 
earlier findings from case reports and open and randomized controlled studies, 
summarized in several reviews (see turk 2003; Jan & Freeman 2004; Phillips & 
Appleton 2004; Wassmer & Whitehouse 2006; Sajith & Clarke 2007), with similar 
positive outcomes.
Getting to sleep a mean of 30 minutes earlier is a statistically significant 
difference, but one might ask whether this is of a meaningful benefit to the 
individuals and their parents or caregivers. In five studies information was given 
on parental perception of the results (Coppola et al. 2004; Garstang & Wallis 
2006; Wasdell et al. 2008; Braam et al. 2008-I; Braam et al. 2008-II). Parents and 
caregivers reported that they spent less time and effort in getting their child to 
stay in bed, while daytime behaviour and alertness on the part of the child also 
improved. Furthermore, compared to placebo, melatonin improved ratings on 
several functional and health dimensions as well as on ratings of severity and 
impact of sleep disorder on family stress.
Across studies, timing of melatonin administration was different and 
various doses of melatonin were given. Both could have influenced the efficacy 
of melatonin. Melatonin is a chronobiotic drug with hypnotic properties (Wirz-
Justice & Armstrong 1996). However, none of the included studies specifically 
mentioned which of these two properties was the main object of the study. this 
is an important issue, because time of administration of melatonin can influence 
the effect of melatonin therapy. Difference in timing of melatonin administration, 
however, did not affect the results of the meta-analysis. Outcomes of studies with 
fixed times of administration were similar to those of studies with varying times 
of administration. there was also no association between melatonin dose and 
the effect on sleep parameters in the studies that were included in this meta-
analysis. this is in line with results of a randomized study (Laakso et al. 2007, 
not included in this meta-analysis), that compared the efficacy of three different 
melatonin doses (i.e. 1, 3, and 5mg) in adults with intellectual disability, given 
30 minutes before the desired bedtime. It showed no difference in effectiveness 
among these three melatonin doses. Another study of elderly persons with sleep 
problems (Zhdanova et al. 2001), without intellectual disability, comparing 
0.3 and 3.0mg of melatonin given half an hour before each participant’s fixed 
bedtime, found that the lower dose was more effective. this suggests that the 
positive effect of exogenous melatonin in these two studies mainly resulted from 
its chronobiological effect. this is in contrast to results of a study on individuals 
with sleep problems and intellectual disability (Coppola et al. 2004), in which 
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parents and caregivers were allowed to increase the dose up to 6mg or even 9mg 
in subsequent phases, in case of inefficacy of the 3mg dose in the first phase 
of the study. In the last phase of the study, in 17 out of 24 (70.8%) participants, 
dose had been increased. Because in this study melatonin was given at bedtime, 
the tendency to increase the dose suggests that the positive effect of exogenous 
melatonin in this study mainly resulted from its hypnotic effect. 
Patient groups in studies included in this meta-analysis were very 
heterogeneous. In five studies a mixed population of patients with intellectual 
disabilities was included (Camfield et al. 1996; Dodge & Wilson 2001; Coppola 
et al. 2004; Wasdell et al. 2008; Braam et al. 2008-I), and four studies examined 
specified groups with disorders in which sleep problems have a relative high 
prevalence (i.e. Angelman syndrome [Braam et al. 2008-II], autism spectrum 
disorder [Garstang & Wallis 2006], Rett syndrome [McArthur & Budden 1998], 
and tuberous sclerosis [O’Callaghan et al. 1999]). In Angelman syndrome, Rett 
syndrome, and tuberous sclerosis, epileptic seizures are frequent and nocturnal 
seizures can cause poor sleep maintenance. this could have influenced the 
efficacy of melatonin treatment. Results of melatonin in these three studies, 
however, were in line with the results in the studies with a mixed population 
of patients with intellectual disability. this can, at least in part, be caused by an 
anticonvulsant effect of melatonin (Gupta et al. 2005).
three recent meta-analyses on the efficacy of melatonin in individuals without 
intellectual disability found that there is no evidence that melatonin is effective 
in treating most sleep disorders (Buscemi et al. 2005 and 2006), or only found 
small differences that seem to be of minor clinical importance (Brzezinski et 
al. 2005). there are several possible explanations for this discrepancy between 
positive results with melatonin in individuals with sleep problems and intellectual 
disability and lack of positive results in individuals without intellectual disability. 
the first is that many studies in individuals without intellectual disability were 
performed in a sleep laboratory using polysomnography. Visual inspection of the 
standard forest plots, as presented in the three meta-analyses in individuals without 
intellectual disability, suggests that the change in sleep latency in studies in which 
measurements were performed in a sleep laboratory using polysomnography is 
smaller compared with studies that were performed under home conditions. Re-
analyzing the data presented in these studies shows that the mean change in sleep 
latency in the studies using polysomnography is 10.1 minutes, whereas change in 
sleep latency in studies performed under home conditions is 16.8 minutes. the 
inclusion of a substantial number of studies using polysomnography in the meta-
analyses in individuals without intellectual disability may have contributed to the 
smaller decrease in sleep latency compared with our meta-analysis, in which all 
studies were performed under home conditions.
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A second explanation is the inclusion of studies on individuals with non-
circadian rhythm sleep disorders, or no sleep problems at all, in the meta-analyses 
in individuals without intellectual disability. A circadian rhythm sleep disorder 
(CRSD) is defined as a persistent or recurrent pattern of sleep disturbance due 
primarily to alterations in the circadian timekeeping system or a misalignment 
between the endogenous circadian rhythm and exogenous factors that affect 
the timing or duration of sleep (American Academy of Sleep Medicine 2005). 
Exogenous and endogenous factors can contribute to misalignment between 
the timing of internal circadian rhythms and the desired (from the parent’s 
or caregivers perspective) time for sleep (Sack et al. 2007). In individuals with 
intellectual disability both endogenous as well as exogenous factors play an 
important part, whereby sleep problems caused by endogenous factors can be 
difficult to treat because they are externally maintained, for example by co-sleeping. 
In individuals with intellectual disability the prevalence of circadian rhythm sleep 
disorders is much higher than in individuals without intellectual disability (Jan 
& Freeman 2004; Sajith & Clarke 2007). Because melatonin is more effective in 
CRSD than other sleep disorders, it could be more effective in individuals with 
sleep problems and intellectual disability, than in some individuals with sleep 
problems without intellectual disability.
A third possible explanation for differences in results between studies in 
sleep problems in patients with and without intellectual disability may lie in 
the type of intellectual disability, i.e. the neurodevelopmental disorder, itself. 
First, maintaining a 24-hour circadian rhythm is based on a complex regulation 
system and many pathophysiological factors can disrupt this system (Claustrat et 
al. 2005). Second, sleep maintenance, i.e. getting back to sleep in case of wakes 
or arousals at night, has to be learned. Children with autism and patients with 
moderate or severe intellectual disability are easily aroused up to a stage that it 
becomes more difficult to fall asleep again independently. Also, low nocturnal 
melatonin levels can have a causal relation with sleep maintenance problems. For 
example, in Angelman syndrome, nocturnal melatonin levels are low (Zhdanova 
et al. 1999). the same applies to persons with autism, in whom, recently, an 
abnormal melatonin synthesis, leading to low nocturnal melatonin levels, was 
found (Melke et al. 2007). It is possible that increasing a low melatonin level to 
a more normal physiological level, leads to less arousals that interfere with sleep 
maintenance. this is supported by results of a study that found that response to 
melatonin treatment in patients with intellectual disability with lower endogenous 
melatonin levels was better than in such patients with higher melatonin levels 
(Laakso et al. 2007).
Except for two parallel studies (Braam et al. 2008-I, Braam et al. 2008-II) all 
other studies were crossover studies. A crossover design is inappropriate when 
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evaluating the efficacy of melatonin (Kunz et al. 2004) because of the possibility of 
a carry-over effect. In two studies included in this meta-analysis, specific attention 
was given to this possibility, by analyzing the results by grouping the participants 
according to the drug-order (Coppola et al. 2004; Wasdell et al. 2008). Both studies 
found tendencies to carry-over effects on some parameters in participants who 
received placebo following melatonin. Laakso et al. (2007) in a study on individuals 
with sleep problems and intellectual disability (not included in this meta-analysis 
because no suitable quantitative data were provided), found tendencies to carry-
over effects on all parameters in participants who received placebo following 
melatonin. A carryover effect was also found in a study on individuals with sleep 
problems without intellectual disability in participants who received placebo after 
melatonin (Kunz et al. 2004). Although carry-over effects may have influenced 
the results in the crossover studies included in this meta-analysis, this does not 
threaten the validity of the conclusions of these studies, nor of this meta-analysis. 
After all, carry-over effects only lead to smaller differences in efficacy between 
melatonin and placebo groups, and as a result, to a smaller statistically significant 
difference in melatonin efficacy than in parallel studies.
this is the first meta-analysis of melatonin in individuals with sleep problems 
and intellectual disabilities. Quality of the studies included was thoroughly 
assessed. Nevertheless there were some limitations. First, conclusions in 
this meta-analysis are based on nine studies with relatively small numbers of 
participants. In connection with this limitation it should, however, be noted that 
this reflects the difficulties in recruitment of participants in these type of studies. 
Second, most studies in this meta-analysis included only or mainly children, and 
meta-analyses in individuals with sleep problems without intellectual disability 
have included mainly adult participants. Because there is a physiological decrease 
in melatonin amplitude with age, we specifically looked into this possible bias. 
Given the fact that melatonin amplitude decreases with age, one might expect 
that because of these lower levels, if related to sleep problems at all, exogenous 
melatonin in adults would have resulted in a better therapeutic result than 
in children. However, outcome of studies in adults with sleep problems and 
intellectual disability included in this meta-analysis was less favorable than studies 
in with children intellectual disability. therefore, it is unlikely that the difference 
in results between this meta-analysis and the meta-analyses in patients with 
sleep problems without intellectual disability can be explained by the inclusion 
of different age-groups, although differences in melatonin receptor sensitivity 
(Pandi-Perumal et al. 2008) cannot be ruled out as the causative factor. 
the included studies were of short duration (10–28 days), so that neither 
information on the effectiveness of long-term melatonin therapy, nor any indication 
on the time needed to resolve the sleep problems, can be given. However, in one long-
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term follow-up study (Carr et al. 2007) in which children with intellectual disability 
were followed every 3 months for up to 3 years 9 months after a randomized trial 
(Wasdell et al. 2008), all parents remained satisfied with the results and adverse 
reaction to melatonin therapy and development of tolerance were not evident.
Polysomnography, the criterion standard to establish the effects of melatonin 
on sleep, was not used in the included studies in this meta-analysis, because 
many children and adults with intellectual disability do not tolerate this 
procedure. However, the other methods (i.e. actigraphy and sleep diaries) are 
reliable methods to establish shifts in sleep-wake rhythm (Littner et al. 2002). In 
seven out of the nine included studies in this meta-analysis diaries to collect sleep 
parameters were used, while in two studies sleep diaries as well as actigraphy 
were used. In one of these two studies (Wasdell et al. 2008) the primary outcome 
measure was felt to be best measured by the caregiver-completed diaries, while in 
the other study (McArthur & Budden 1998) actigraphy was said be more reliable 
at monitoring sleep parameters than caregiver diaries. Diary measures obviously 
have measurement errors, but are frequently used in non-clinical settings. Sleep 
diaries based on observations by others, however, yield more satisfactory data 
than sleep diaries based on self-report (Ancoli-Israel et al. 2003). Besides, parents 
of sleep-disturbed infants can be accurate reporters of actigraphically-assessed 
sleep onset and sleep duration. Sadeh et al. (1991) showed an 85.3% agreement 
rate between actigraphic sleep-wake scorings and those of polysomnography. 
therefore, we believe diary measures based on observations by parents and other 
caregivers can be used in assessing sleep parameters.
Publication bias and heterogeneity are major concerns for meta-analysis 
(Begg & Berlin 1988; Greenland 1994). We included only studies that had good 
methodological quality as indicated by the Downs and Black checklist (Downs & 
Black 1998). In addition, we examined publication bias and statistical heterogeneity 
and found that they did not substantially bias the outcomes of the meta-analyses 
reported. However, as can be seen from the low number of participants in some 
of the included studies, the statistical power is intrinsically not very high. As 
a result, the outcomes of this meta-analysis should only cautiously be applied 
in clinical practice. We advocate that more methodologically sound placebo-
controlled randomized trials on melatonin should be conducted in the future, 
as this is of major importance for treating sleep problems in individuals with 
intellectual disability.
conclusion
In spite of the heterogeneity of the studies, regarding patient groups, melatonin 
preparations, dosage, and timing of administration, the results of this meta-
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analysis indicate that melatonin is effective and safe in the treatment of sleep 
problems in individuals with intellectual disability, at least in short-term 
treatment. Although melatonin can be prescribed safely in individuals with sleep 
problems and intellectual disability, prescribers should realize that melatonin is a 
non-licensed drug in most countries, and that its long-term treatment effects are 
still unknown. therefore, we advise the prescription of melatonin in individuals 
with sleep problems and intellectual disability preferably when it has been tried to 
assess the biological clock by (salivary) dim light melatonin onset measurements 
(Pandi-Perumal et al. 2007) and in randomized clinical trials. Future studies 
should assess melatonin dose and timing, circadian rhythm parameters, and 
quality of life of patients with intellectual disabilities and their caregivers.
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MELAtONIN tREAtMENt IN INDIVIDUALS WItH 
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abstract
Background While several small-number or open-label studies suggest that 
melatonin improves sleep in individuals with intellectual disabilities (ID) with 
chronic sleep disturbance, a larger randomized control trial is necessary to 
validate these promising results.
Methods the effectiveness of melatonin for the treatment of chronic sleep 
disturbance was assessed in a randomized double-blind placebo-controlled trial 
with 51 individuals with ID. All of these individuals presented with chronic 
idiopathic sleep disturbance for more than 1 year. the study consisted of a 1-
week baseline, followed by 4 weeks of treatment. Parents or other caregivers 
recorded lights off time, sleep onset time, night waking, wake up time and 
epileptic seizures. Endogenous melatonin cycle was measured in saliva before 
and after treatment. 
Results Compared with placebo, melatonin significantly advanced mean sleep 
onset time by 34 min, decreased mean sleep latency by 29 min, increased mean 
total sleep time by 48 min, reduced the mean number of times the person awoke 
during the night by 0.4, decreased the mean duration of these night waking 
periods by 17 min and advanced endogenous melatonin onset at night by an 
average of 2.01 h. Lights off time, sleep offset time and the number of nights 
per week with night waking did not change. Only few minor or temporary 
adverse reactions and no changes in seizure frequency were reported.
Conclusions Melatonin treatment improves some aspects of chronic sleep 
disturbance in individuals with ID.
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introduction
Sleep problems are more common in persons with intellectual disabilities (ID) 
than among the general population. Prevalence rates for individuals with ID 
range from 15% to 88% depending on study design, participant characteristics 
and definition of sleep problems (e.g. Bartlett et al. 1985; Clements et al. 1986; 
Piazza et al. 1996; Didden et al. 2002). In contrast, the prevalence of sleep 
problems in the general population varies from 10% to 40% (Simon & VonKorff 
1997). Compared with persons with ID without sleep problems, persons with 
ID and sleep problems exhibit more daytime behavioural problems, irritability 
and lethargy. Furthermore, their ability to function optimally is diminished (e.g. 
Didden et al. 2002; Doran et al. 2006). Sleep problems do not only negatively 
affect the individuals themselves, but also affect their family and other caregivers 
(Quine 1991).
Sleep problems in individuals with ID are often characterized by disruptions 
in the circadian sleep–wake cycle. the prevalence of circadian rhythm disorders 
in individuals with ID is higher than in the general population (Jan & Freeman 
2004). Because of the presence of the ID it may be difficult to teach the child 
to develop and maintain an adequate sleep–wake behaviour and rhythm. Next 
to this, there are several somatic factors that may cause sleep problems, such 
as gastro-oesophageal reflux (Bohmer et al. 1999), epileptic seizures (Espie & 
tweedie 1998), periodic limb movement disorder (Miano et al. 2005) and sleep 
apnea syndrome (De Miguel-Diez et al. 2003).
Sleep problems in individuals with ID are often complex and usually more 
difficult to treat than in typically developing individuals. Behavioural treatments 
can be effective (Montgomery et al. 2004). Sedatives are often prescribed, but 
may cause serious side effects (Matson et al. 2000). Because individuals with 
ID often take other medications, the risk of drug interactions is increased. this 
may result in daytime sedation, increased risk of sleep related breathing disorder 
and increasing behavioural problems (Dodge & Wilson 2001; Doran et al. 2006). 
therefore, effective sleep medication that does not have adverse side effects is 
needed. 
Melatonin, a hormone synthesized and released by the pineal gland during 
darkness, is a chronobiotic drug with hypnotic properties (Wirz-Justice & 
Armstrong 1996). Melatonin secretion is regulated by an endogenous pacemaker 
in the suprachiasmatic nuclei of the hypothalamus. Information on the light/
dark cycle through the retino-hypothalamic tract is needed to synchronize its 
circadian rhythm to 24 h. Many pathophysiological situations can disturb this 
complex regulation system and cause dysfunction of the sleep–wake system 
(Claustrat et al. 2005). Melatonin levels in serum or saliva, collected under 
dim light conditions, are used to assess the phase of the endogenous circadian 
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pacemaker. Exogenous melatonin can affect the phase of the sleep–wake cycle. 
It causes a phase advance when administered before dim light melatonin onset 
(DLMO) in the late afternoon or early in the evening and a phase delay occurs 
after giving melatonin in the early morning (Lewy et al. 1992). 
Several uncontrolled studies suggested that melatonin improves sleep in 
individuals with ID and sleep disturbance (Palm et al. 1997; Ishizaki et al. 1999; 
Miyamoto et al. 1999; Zhdanova et al. 1999; Jan 2000; Pillar et al. 2000; Ramstad 
& Loge 2002; Ross et al. 2002; De Leersnijder et al. 2003). Clinical improvement 
was reported in 69–100% of the cases, although results were mostly based on 
small samples. Up to now, only a few randomized trials with melatonin in 
persons with ID have been conducted, with mostly small numbers of participants 
(Camfield et al. 1996; McArthur & Budden 1998; O’Callaghan et al. 1999; Dodge 
& Wilson 2001; Niederhofer et al. 2003; Coppola et al. 2004; Garstang & Wallis 
2006). In most trials, a significant reduction of sleep latency and an increase in 
total sleep time were reported, whereas the influence on night wakes (NWs) was 
limited. Unfortunately in these studies conclusions were drawn on small sample 
sizes, DLMO was not measured, and the influence of exogenous melatonin on 
the endogenous melatonin rhythm was not studied. therefore, in the present 
study effectiveness of exogenous melatonin is assessed in a randomized double-
blind placebo-controlled study in a relatively large sample of individuals with ID 
(i.e. n = 51), measuring DLMO and the influence of exogenous melatonin on the 
endogenous melatonin rhythm.
Methods
Participants and selection
Individuals with chronic sleep disturbance were referred to our sleep center by 
local general practitioners and ID physicians. Participants were examined by the 
first author, a physician for individuals with ID and specialized in sleep disorders 
in ID individuals. Participants were included when anamnesis ruled out somatic 
and psychiatric causes for the sleep disturbance and standard behavioural 
treatment and sleep hygiene measures had been unsuccessful. Individuals 
were included if they had (1) sleep latency of 30 min or more; or (2) two or more 
periods of NW that lasted more than 45 min each night; or (3) five or more NWs 
lasting more than 15 min each night, during at least five nights each week. Sleep 
disturbance was present for the duration of at least 1 year. the level of ID was 
based on the developmental age equivalent on the Social Functioning Scale for 
the Mentally Retarded, SRZ (Kraijer et al. 1994), which was administered as part 
of the study. 
Exclusion criteria were prior use of melatonin, restless leg syndrome, sleep 
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apnea syndrome, liver disease, renal failure, chronic pain and age less than 24 
months. Individuals with Smith–Magenis syndrome were also excluded, because 
their sleep disorder is associated with an inversion of the circadian rhythm 
of melatonin and should be treated with both melatonin and a selective beta-
adrenergic blocker (De Leersnijder et al. 2003).
the trial consisted of two consecutive periods: (1) a 1-week qualification or 
baseline period; and (2) 4 weeks of treatment during which participants were 
randomly allocated to either the melatonin or placebo condition. Participants 
were allowed to go to bed if they asked for it or if they seemed obviously sleepy, 
instead of at a predetermined scheduled time. All medications were held constant 
during all study phases.
Participants were randomized in blocks of 10 to keep possible time effects to 
a minimum. All investigators involved in the present study were unaware of the 
treatment allocation. the code was broken when the data of all individuals were 
recorded in the database. the trial was performed in the home setting of each 
individual, and was conducted according to the European Guidelines for Good 
Clinical Research Practice in children (Committee for Proprietary Medicinal 
Products 1997) and followed the 1983 revised provisions of the 1975 Declaration 
of Helsinki. the study was approved by the local Medical Ethical Committee. 
Written informed assent was obtained for all carers.
Treatment
During the 4-week treatment, individuals aged 6 years and older daily received 
5-mg melatonin (Duchefa Farma BV, Haarlem, the Netherlands) mixed with 
carboxymethylcellulose in a fast release tablet, or an identically looking placebo, 
at 7 p.m. A 5-mg dose was chosen because most placebo- controlled published 
trials with melatonin used this dose (see Dahlitz et al. 1991; Nagtegaal et al. 1998-
I; Smits et al. 2001; Van Wieringen et al. 2001). Individuals aged under 6 years 
received a daily dose of 2.5-mg melatonin orally at 6 p.m. Compliance was tested 
by comparison of the number of tablets returned with the number prescribed.
Outcome measures
Primary outcome measures were sleep latency (min), sleep onset time, wake up 
time, total sleep time and number and duration of NWs. Secondary outcome 
measures were salivary melatonin concentrations, number of epileptic seizures (if 
applicable) and adverse reactions of trial medication. Parents or other caregivers 
recorded the time that the lights went off, sleep latency, number and duration of 
NWs and wake up time in a sleep diary. they were asked to listen to or observe 
their child or patient every 10 min from bedtime until the time they found their 
child or patient asleep. Furthermore, they reported the times at night when they 
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heard or saw that the child or patient was awake. the parents or other caregivers 
were encouraged to describe any suspected adverse effects in the diary.
Results were discussed with parents or other caregivers at the end of the double-
blind phase. to assess a possible pro-convulsant effect of exogenous melatonin, 
seizure control was asked for at any visit (Sheldon 1998).
Endogenous melatonin
to assess change in circadian phase, salivary samples were collected hourly during 
five consecutive hours on the last night of the baseline week and the last night of 
the fourth treatment week, when no study medication has been given. In children 
aged 2–4 years samples were collected from 5 p.m., in children aged 5 and 6 years 
from 6 p.m., in children aged 7–14 years from 7 p.m. and in participants aged 
15 years and older from 8 p.m. to prevent suppression of melatonin secretion 
by bright light (Bojkowski et al. 1987), children remained indoors with curtains 
closed during this period. Dim light (<50 lux) was allowed. Saliva was collected 
in a cotton plug chewed on either by the patient, or by sweeping the cavity of the 
individuals’ mouth by one of the parents or other caregivers. 
the limit of detection of the assay, which had to contain at least 0.5 mL of 
saliva, was 0.39 pg/mL with an intra-assay variation of 14.5%/mL (Ruger et al. 
2003). the maximum detection level was 50 pg/mL. DLMO was defined as the 
first time at which salivary melatonin reached 4 pg/mL. DLMO was calculated as 
the linearly interpolated time of the first sample above 4 pg/mL that was preceded 
by a lower value (Nagtegaal et al. 1998-II). In several individuals it was not possible 
to calculate DLMO because their melatonin levels were either all lower than 4 pg/
mL or above 4 pg/mL. therefore, in case all samples of an individual patient were 
above 4 pg/mL, we decided to set DLMO time at 0.5 h prior to the collection time 
of the first sample. In case all samples were lower than 4 pg/mL, DLMO was set 
at 0.5 h after the time of the last sample. 
Statistical analyses
Results of a one-sample Kolmogorov–Smirnov test showed that the data of 
each variable were normally distributed. T-tests for independent samples were 
conducted to test differences in change between melatonin and placebo treatment 
on the sleep variables. Statistical significance was accepted at P < 0.05.
results
A total of 77 children and adults with ID and chronic sleep problems were referred 
to our sleep center (see Fig. 1). After receiving information on the design of the 
trial, parents or other caregivers of 10 individuals decided not to participate. 
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Figure 1: Selection and allocation of participants
(N = 5)
Melatonin
(N = 25)
Placebo
(N = 18)
(N = 1)
(N = 30)
Informed consent withdrawn
(N = 1)
Insufficient dataInsufficient data
(N = 58)
Not eligible
(N = 3)
(N = 4)
Smith Magenis syndrome
Patients randomized
Placebo
(N = 28)
Melatonin
Referred to sleep centre
Refused participation
(N = 77)
(N = 12)
(N = 65)
Total undergoing screening
Secondary sleep disorder
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Parents of two children thought that the trial was too burdensome for their 
children.
Sixty-five individuals were screened for possible inclusion in our study. three 
individuals were excluded because of an untreated co-morbidity that probably 
was responsible for the chronic sleep problems (e.g. gastro-oesophageal reflux, 
congestive heart failure, anxiety disorder) and four children because of Smith–
Magenis syndrome.
Fifty-eight individuals were randomly assigned to melatonin or placebo 
conditions. During the baseline week parents of one child withdrew informed 
consent because their child refused to cooperate with saliva sampling. Five 
individuals in the placebo group and one in the melatonin group had to be 
excluded because parents or other caregivers did not complete the sleep logs. 
the remaining melatonin treatment group consisted of 29 participants (19 
males, 10 females), aged 2–78 years (mean age 23.2 years, SD = 21.4), of whom 17 
(58.6%) were 19 years or younger and 12 (41.4%) were 20 years or older. the severity 
of ID was assessed as profound (n = 9), severe (n = 11), moderate (n = 4) and mild 
(n = 5). twenty-one individuals showed sleep onset as well as sleep maintenance 
Table 1: Primary diagnoses intellectual disabilities
Aetiology
Autism 1
Cerebral palsy 5 4
Genetic syndrome 10 9
18q- deletion syndrome 1
Angelman syndrome 4
ATR-X syndrome 1
Bardet Biedl syndrome 1
Down syndrome 3 5
Prader-Willi syndrome 1
Sanfilippo syndrome 1 2
Other known causes 2 3
Congenital hypothyreoidism 1
Hydrocephalus 1
Hypopituitarism 1
Rubella syndrome, congenital 1 1
Mental retardation of unknown cause 11 6
Placebo
(n=22)
Melatonin
(n=29)
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problems, five individuals had sleep onset problems only and three suffered from 
sleep maintenance problems only. Sixteen individuals used anticonvulsants, of 
which nine were free of seizures for at least 1 month preceding the start of the 
trial.
the placebo group consisted of 22 individuals (9 males, 13 females), aged 2–58 
years (mean age 20.9 years, SD = 18.2), of whom 13 (59.1%) were 19 years or 
younger and 12 (40.9%) were 20 years or older. the severity of ID was profound 
(n = 9), severe (n = 3), moderate (n = 3) and mild (n = 7). ten individuals showed 
sleep onset as well as sleep maintenance problems, six had sleep onset problems 
only and six suffered from sleep maintenance problems only. Six individuals used 
anticonvulsants, of which three individuals were free of seizures for at least 1 
month preceding the trial. 
the primary diagnoses of the ID are summarized in table 1.
Compared with placebo treatment, during melatonin treatment mean sleep 
latency decreased 29 min, mean sleep onset advanced 34 min and mean total 
sleep time increased 48 min. the mean number of NWs per night decreased 
with 0.42 and the mean duration of NWs decreased with 17 min (table 2). DLMO, 
calculated according to Nagtegaal et al. (1998-II), advanced 1.39 h (table 3). there 
was no significant change in lights out time, number of nights with NWs per 
week and sleep offset time compared with baseline. 
there was a significant correlation between baseline DLMO and the change in 
Table 3: Number of patients with different dim light melatonin onset (DLMO) calculations
Group Baseline Week 4
DLMO<4 m 8 1
p 9 4
DLMON m 15 7
p 4 9
DLMO>4 m 2 17
p 2 2
Insufficient saliva for m 4 4
  melatonin analysis p 7 7
51 51
DLMO<4, not possible to calculate dlmo because all melatonin levels were < 4,0 pg/mL
DLMON, dlmo calculated according to Nagtegaal et al. 1998b
DLMO>4, not possible to calculate dlmo because all melatonin levels were > 4,0 pg/mL
CHAPtER 3
51
DLMO between baseline and week 4 in the melatonin group (r = 0.75, P < 0.001). In 
individuals with a late DLMO, melatonin treatment resulted in a greater advance of 
DLMO than in individuals with a normal DLMO. However, there were no significant 
correlations between baseline DLMO and change in the other sleep parameters.
Parents or caregivers of 20 individuals (i.e. 69%) in the melatonin group and 19 
(i.e. 90%) individuals in the placebo group correctly identified at the end of week 
4 whether melatonin or placebo was given. In the melatonin group, parents and 
caregivers of five individuals reported an increase of daytime crying, restlessness 
and burping and a decrease of appetite. Parents of one patient in the placebo 
group reported development of restless legs. the parents or caregivers considered 
these effects as temporarily and minor important. Parents and caregivers of 14 
individuals in the melatonin group reported an improvement in mood, vigilance 
and/or daytime behavioural problems and found their children or individuals 
easier to manage with less settling problems at bedtime. these effects were 
not reported by parents or caregivers in the placebo group. Parents of one child 
with infantile spasms (West syndrome) in the melatonin group reported a 50% 
decrease in seizure frequency after 4 weeks of treatment. At follow-up consultation 
1 month later, this beneficial effect on seizure frequency was still present. Seizure 
frequency in the other 15 individuals with epilepsy did not change.
discussion
In this study, melatonin was highly effective in the treatment of chronic sleep 
problems in a large sample of individuals with ID. Results from statistical analyses 
showed that compared with placebo melatonin decreased sleep latency, advanced 
both sleep onset and melatonin onset time and increased total sleep time. these 
results corroborate those found in other studies using melatonin.
In four out of five randomized trials in individuals with ID (i.e. McArthur 
& Budden 1998; Dodge & Wilson 2001; Coppola et al. 2004; Garstang & Wallis 
2006) there was a significant reduction in sleep latency, whereas O’Callaghan et 
al. (1999) reported only a small and non-significant reduction in sleep latency. 
Only one trial (i.e. Garstang & Wallis 2006) reported a reduction in the number 
of NWs per night. In all five trials that presented information on total sleep time 
melatonin increased total sleep time (Camfield et al. 1996; McArthur & Budden 
1998; O’Callaghan et al. 1999; Coppola et al. 2004), although the increase was 
statistically significant in three trials only. Niederhofer et al. (2003) reported a 
significant increase in sleep efficiency, whereas Dodge & Wilson (2001) did not 
find a significant increase in total sleep time.
the advanced sleep onset and DLMO after 4 weeks of treatment in the 
melatonin group are consistent with an advanced sleep–wake cycle owing to 
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the chronobiotic properties of melatonin (Wirz- Justice & Armstrong 1996). the 
decrease in sleep latency may be explained by both the soporific and chronobiotic 
properties of melatonin (Wirz-Justice & Armstrong 1996).
In previous studies, melatonin has not been shown to influence sleep 
maintenance. It should be noted, however, that most of these placebo-controlled 
studies included individuals with so-called Delayed Sleep Phase syndrome. In this 
type of circadian rhythm disorder sleep maintenance is normal. the reduction of 
number and mean duration of wakes per night in the melatonin group in the 
present study suggests that melatonin may also influence sleep maintenance.
Exogenous melatonin affects the phase of the sleep–wake cycle (Lewy et al. 
1992). Successful use of melatonin in order to shift sleep–wake rhythms requires 
correct timing of treatment relative to internal circadian rhythms (Lewy et al. 1992). 
Melatonin advances sleep–wake rhythms most powerfully when administered 5 
h before endogenous melatonin starts to rise in dim light (DLMO) and delays 
sleep–wake rhythm most when given 10 h after DLMO.
An average of half an hour earlier getting to sleep and sleeping nearly 1 h 
longer is a statistical significant difference, but one might ask whether this is of 
a meaningful benefit to the individuals and their parents or caregivers. When 
asked whether they were satisfied with the results after 4 weeks of melatonin, 
parents and caregivers of all individuals with a decrease in sleep latency of 20 min 
or more were very satisfied with this result. they needed less time-consuming 
efforts to let their child or patient stay in bed. Also, a mean increase in total sleep 
time by 48 min resulted in fewer or no incidents in which others were disturbed 
in their sleep.
this is the first study with melatonin in which DLMO is reported for individuals 
with ID. DLMO measures circadian timing and is crucial for the chronobiotic 
properties of melatonin (Arendt 2006). the correlation between baseline DLMO 
and the advancement of DLMO during melatonin treatment found in our study 
is an expression of these chronobiotic properties (Van Der Heijden 2005). In this 
study, we used a parallel groups design. We did not use a crossover design because 
this design requires several weeks after discontinuing exogenous melatonin 
administration for symptoms of sleep disorders to return (Kunz et al. 2004). A 
crossover design may influence the results in the placebo phase in those who have 
started with melatonin in the first phase of the trial. this can be responsible for 
a less significant treatment result in a study with a crossover design, when only a 
1-week wash-out period is used.
Several limitations of our study need consideration. First, we used diaries 
to measure sleep. Diary measures obviously have measurement errors, but are 
frequently used in non-clinical settings. Sleep diaries based on observations by 
others, however, yield more satisfactory data than sleep diaries based on self-
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report (Ancoli-Israel et al. 2003). Besides, parents of sleep-disturbed infants were 
accurate reporters of actigraphically assessed sleep onset and sleep duration. 
Sadeh et al. (1991) showed an 85.3% agreement rate between actigraphic sleep–
wake scorings compared with those of polysomnography. therefore, we think 
diary measures based on observations by parents and other caregivers can be 
used in assessing sleep parameters. We did rule out sleep apnea, restless legs 
syndrome, chronic pain and other causes of insomnia, based on anamnesis. We 
could not perform polysomnography because the burden of this technique was 
too heavy for the individuals or their caregivers.
Second, successful salivary DLMO measurements were not possible in all 
individuals. In several individuals it was not possible to obtain enough saliva. 
In other individuals salivary melatonin concentrations were below the detection 
limit during the period of collecting. In these individuals saliva should also be 
collected later during the night. However, sufficient measurements could be 
made to draw conclusions.
A third limitation is that the influence of melatonin on daily health status, 
both of participants and caregivers, was not assessed systematically. Studies are 
needed to confirm the findings of the placebo-controlled trial in children (Smits 
et al. 2003) and the open-label study in adults suggesting that melatonin improves 
quality of life. And finally, the relative short baseline of 1 week could be mentioned 
as a limitation, as well as the randomization, that did not take account of age, 
gender and developmental stage. We recommend to do so in further studies. 
In conclusion, the present study indicates that melatonin improves sleep in 
individuals with ID that suffer from chronic sleep disturbance, probably mainly 
because of its chronobiotic effects. the limitations of our study, especially the 
way of randomization, limit the general applicability of its results. Nevertheless, 
we recommend to consider treatment with melatonin in individuals with ID 
that suffer from chronic sleep disturbance, especially when DLMO is delayed 
preferably in well-performed scientifically based trials.
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abstract
Background Previous studies suggested that melatonin improves sleep in 
insomniac patients with Angelman syndrome. 
Method to assess the efficacy of melatonin, a randomized placebo-controlled study 
was conducted in 8 children with Angelman syndrome with idiopathic chronic 
insomnia. After a 1-week baseline period, patients received, depending on age, 
either melatonin 5 or 2.5 mg, or placebo, followed by 4 weeks of open treatment. 
Parents recorded lights off time, sleep onset time, wake-up time, and epileptic 
seizures in a diary. Salivary melatonin levels were measured at baseline and the 
last evening of the fourth treatment week. 
Results Melatonin significantly advanced sleep onset by 28 minutes, decreased 
sleep latency by 32 minutes, increased total sleep time by 56 minutes, reduced 
the number of nights with wakes from 3.1 to 1.6 nights a week, and increased 
endogenous salivary melatonin levels. Parents were satisfied with these results. 
Discussion Indications that melatonin dose in Angelman syndrome patients 
should be low, are discussed.
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introduction
Angelman syndrome is characterized by severe intellectual disability, motor 
impairment, seizures and subtle dysmorphic facial features and is associated 
with 4 types of chromosomal abnormalities involving the chromosome 15q11-q13 
region (deletions, paternal uniparental disomy, methylation imprinting mutations, 
and UBE3A and other presumed single gene mutations). Most individuals with 
Angelman syndrome exhibit behavioral features such as excessive laughter, 
hyperactivity, noncompliance, speech impairment, and sleep problems (Clayton-
Smith & Laan 2003; Didden et al. 2004-I; Summers et al. 1995). Sleep problems 
include settling problems and frequent night waking (Didden et al. 2004-II; Bruni 
et al. 2004). they appear resistant to behaviour therapy and conventional sleep 
medication (Didden et al. 2004-II).
Melatonin, a hormone synthesized and released by the pineal gland during 
darkness, is a chronobiotic drug with hypnotic properties (Wirz-Justice & 
Armstrong 1996). there is increasing evidence that chronic sleep problems in 
persons with intellectual disabilities are the result of circadian rhythm disorders 
and that melatonin therapy could be effective. However, only a few randomized trials 
with melatonin in persons with intellectual disabilities are performed (Phillips 
& Appleton 2004). In insomniac patients with intellectual disabilities, melatonin 
decreases sleep latency, but does not influence sleep maintenance (Camfield et al. 
1996; McArthur & Budden 1998; Dodge & Wilson 2001). An open-label trial of 13 
children with Angelman syndrome found that melatonin decreased sleep latency 
and increased total sleep time as well (Zhdanova et al. 1999).
Method
Participants
Parents of patients with Angelman syndrome and chronic idiopathic insomnia 
that were referred to our sleep center by local general practitioners, were asked to 
participate in a placebo-controlled trial with melatonin. Criteria for participation 
were sleep latency more than 30 minutes, or 2 or more wakes, lasting more than 
15 minutes a night, at least 5 nights a week, during more than 1 year preceding 
inclusion. Exclusion criteria were prior use of melatonin, liver disease, renal 
failure, chronic pain, and age less than 24 months. Patients were examined by a 
physician (first author) for patients with intellectual disabilities who is specialized 
in sleep disorders, assessing that behavioural and social sleep hygiene measures 
had been attempted unsuccessfully and no signs for a physical cause for the 
insomnia were present. the trial was performed in the home setting of each 
individual. It followed the 1983 revised provisions of the 1975 Declaration of 
Helsinki. the local Medical Ethical Committee approved the study. the patients’ 
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parents gave written informed consent. 
the trial consisted of 2 consecutive periods: a 1-week qualification period 
and 4 weeks of treatment during which participants were randomly allocated 
to melatonin or placebo therapy. Saliva specimens for measuring melatonin 
concentrations were collected in the qualification period (baseline) to examine 
whether there was a delayed sleep phase syndrome or another disturbance in 
melatonin circadian rhythm and at the end of the last week of the treatment period 
to examine whether 4 weeks of treatment had changed endogenous melatonin 
circadian rhythm. After the 4-week placebo controlled phase of the study, all 
patients received 4 weeks open treatment with melatonin. At follow-up parents 
were asked to tell if they were satisfied with the result of the treatment. Patients 
were not allowed to change their co-medication. All investigators involved in the 
study were unaware of the treatment allocation. the code was broken when the 
data of all patients were recorded in the database.
Treatment
During the 4 treatment weeks, patients 6 years of age and older received a daily 
dose of 5 mg of melatonin (Duchefa Farma BV, Haarlem, the Netherlands) 
orally at 7 PM, mixed with carboxymethylcellulose in a fast-release tablet, or 
an identically looking placebo. A 5-mg dose was chosen because most placebo-
controlled trials with melatonin used this dose (Nagtegaal et al. 1998; Dahlitz et 
al. 1991; Smits et al. 2001). Patients under 6 years of age received a daily dose of 
2.5 mg of melatonin orally at 6 PM. Compliance was tested by comparison of the 
number of tablets returned with the number prescribed.
Outcome Measures
Primary outcome measures were the between-group differences of sleep latency, 
sleep onset, wake up time, and number and length of wakes. Secondary outcome 
measures were the between group differences of salivary melatonin concentrations, 
number of epileptic seizures, as well as adverse reactions of melatonin. Sleep 
variables were assessed by parents and recorded in a sleep diary. Parents were 
asked to listen or watch their child every 10 minutes from bedtime until the time 
they found their child asleep. Furthermore, they reported the times at night when 
they heard or saw that their child was awake. the parents were encouraged to 
describe any suspected adverse effects in the diary. Results were discussed with 
parents at the end of the double-blind phase and after 4 weeks of open treatment. 
At both times, parents were asked to judge the result as small, moderate, or strong 
improvement or unchanged. Because of contradictory reports of proconvulsant 
and anticonvulsant effects of exogenous melatonin (Sheldon 1998; Peled et al. 
2001), seizure control was asked for at any visit.
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Endogenous Melatonin
On the last night of the baseline week and the last night of the fourth treatment 
week (at which night no melatonin was given) salivary samples were collected 
hourly during 5 consecutive hours. In children 2–4 years of age from 5 PM, in 
children 5 and 6 years of age from 6 PM, and in older children from 7 PM. to 
prevent suppression of melatonin secretion by bright light (Bojkowski 1987) the 
children remained indoors with curtains closed during that period. Dim light 
(<50 lux) was allowed. Saliva was collected in a cotton plug either chewed on by 
the patient or by sweeping the cavity of the patients’ mouth by 1 of the parents. 
the limit of detection of the assay, which had to contain at least 0.5 mL of saliva, 
was 0.39 pg/mL with an intra-assay variation of 14.5%/mL (Ruger et al. 2003). the 
maximum detection level was 50 pg/mL.
Statistical Analyses
Results of a 1-sample Kolmogorov-Smirnov analysis showed that data of each 
variable were normally distributed. Unpaired t-tests were conducted to test 
differences in change between melatonin versus placebo treatment on the sleep 
variables. Statistical significance was accepted at P < .05.
results
A total of 13 children and adults with Angelman syndrome and chronic sleep 
problems were referred to our sleep center. Four of them were not included 
because their sleep problems did not meet criteria for inclusion. After receiving 
information on the design of the trial, the parents of 1 patient decided not to 
participate because they thought that the trial was too burdensome for their 
child. the remaining 8 patients were randomly assigned to melatonin or placebo 
conditions. thus, the melatonin and the placebo group each consisted of 4 
patients. 
Seven patients showed sleep onset as well as sleep maintenance problems, 
and 1 patient suffered from sleep onset problems only (table 1). there were 
no statistically significant differences between patients who were allocated to 
melatonin and placebo group on all parameters during baseline week.
During melatonin treatment, sleep latency decreased by 32 minutes, sleep 
onset advanced by 28 minutes, and total sleep time increased by 56 minutes on 
average. the mean number of nights with wakes decreased from 3.1 to 1.6 a 
week on average. these changes significantly differed from those during placebo 
treatment (table 2). there was no significant change in lights out time and sleep 
offset time.
the parents of 2 children (#4 and 8) who received melatonin considered the 
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treatment outcome as a moderate improvement, and 2 (#2 and 5) as a strong 
improvement. After 4 weeks of open treatment with melatonin, the parents of 
2 children (#2 and 8) decided upon continuation of the treatment. the parents 
of 1 child (#5), however, reported an increase of the number of night wakes and 
stopped treatment. the parents of the fourth child (# 4) did not want to continue 
treatment, because they were disappointed with the treatment result.
the parents of the 4 children who received placebo reported that the sleep 
problems of their children did not change. After 4 weeks of open melatonin 
treatment, the parents of 3 children (#1, 3, and 6) wanted to continue melatonin 
treatment because of the strong improvement of the sleep of their child, whereas 
the parents of 1 child (#7) stopped treatment because the sleep problems in their 
child remained unchanged.
In 35 of 80 salivary samples, the amount of saliva was too low for a melatonin 
analysis. Visual inspection of the data on the remaining 45 samples (table 3) 
shows that salivary melatonin concentrations, on a day no study medication was 
given, increased substantially after melatonin treatment (i.e., child 2, 4, 5, and 8), 
whereas melatonin concentrations after placebo treatment (i.e., child 1, 3, 6, and 
7) did not change. In patients 4 and 8, salivary melatonin concentrations were 
above 50 pg/mL at the first evening after discontinuation of 4 weeks of melatonin 
treatment. In patient 5, the first sample (collected at 5 PM) contained more than 
50 pg/mL.
Of 4 patients receiving melatonin in the melatonin group, 2 used anti-epileptic 
drugs (i.e., child 5 and 8; see table 1). Last reported seizure was, respectively, 3 
months and 2 years before entering the study. No seizures were reported by their 
parents during the present study, or by parents of the other 6 patients.
discussion
Four weeks of melatonin treatment in Angelman syndrome children with 
chronic insomnia was more effective in decreasing sleep latency, advancing sleep 
onset, and increasing total sleep time than placebo. Furthermore, the number of 
nights per week with wakes decreased more during melatonin treatment. the 
reduction in sleep latency and the advance of sleep-onset is consistent with earlier 
findings in studies with melatonin in children with chronic sleep onset (Smits et 
al. 2001; Smits et al. 2003). the beneficial effect on night waking and total sleep 
time differed from findings in earlier studies showing that melatonin does not 
influence sleep maintenance (Oldani et al. 1994; Camfield et al. 1996; Dodge et al. 
2001; McArthur et al. 1998).
An average of half an hour earlier getting to sleep and sleeping 1 hour longer 
is a statistically significant difference. However, one might ask whether this is 
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of a meaningful benefit to the patients and their parents. When asked whether 
they were satisfied with the results after 4 weeks of melatonin (or in the case of 
placebo after 4 weeks of open melatonin use), parents responded positively. Half 
an hour earlier, getting to sleep meant that parents needed less time-consuming 
efforts to try to let their child stay in bed. A mean increase in total sleep time 
by approximately 1 hour, meant less or not waking up anymore in the middle 
of the night and waking up by parents and siblings. But next to this, parents 
reported that their children’s behaviour was easier to manage and that they were 
less sleepy and more attentive at daytime. this latter finding is consistent with 
another placebo-controlled study showing that melatonin improved health status 
(Smits et al. 2003).
Diary measures have measurement error, but are frequently used in nonclinical 
settings. Sleep diaries based on observations by others, however, yield more 
satisfactory data compared with actigraphy than sleep diaries based on self-report 
(Ancoli-Israel et al. 2003). Besides, parents of sleep-disturbed infants were accurate 
reporters of actigraphically assessed sleep onset and sleep duration (Sadeh 1996). 
Sadeh et al. (1999) showed an 85.3% agreement rate between actigraphic sleep–
wake scorings compared with those of polysomnography. Measures were only 
used to compare between the results of the 2 consecutive periods and not used to 
determine sleep parameters per se.
Melatonin levels in the baseline week were low. It is possible that in our 
patients melatonin levels increased after the last sampling time. Late melatonin 
onset is a key characteristic of the delayed sleep phase syndrome (Smits et al. 
2003). Consequently, sleep onset insomnia in Angelman syndrome could be 
the result of a delayed sleep phase syndrome. Delayed sleep phase syndrome is 
defined as an abnormally delayed sleep–wake rhythm. the major symptoms of 
this syndrome are extreme difficulty to initiate sleep at a conventional hour of 
the night and great difficulty to wake up on time in the morning. Delayed sleep 
phase syndrome is associated with late dim light melatonin onset (Nagtegaal et al. 
1998). this circadian rhythm disorder responds very well to melatonin treatment. 
Zhdanova et al. (1999) also found low melatonin levels in children with Angelman 
syndrome in the baseline week. they attributed these low levels, in part, to the 
use of valproate. Sodium valproate is known to suppress plasma melatonin 
levels (Monteleone et al. 1997). In our study, 4 children used valproate, but their 
melatonin levels in the baseline week were not lower than those of children who 
did not use valproate.
the question whether melatonin influences seizure frequency remains 
a matter of discussion. Melatonin may increase seizure frequency (Sheldon 
1998). However, melatonin also has anticonvulsant effects (Peled et al. 2001). 
the melatonin treatment period in our patients was perhaps too short to draw 
CHAPtER 4
69
conclusions about the influence of melatonin on seizure frequency.
In 3 of the 4 children who received melatonin, salivary melatonin levels were 
extremely high after 4 weeks of treatment. the parents of these children reported 
the return or increase of night wakes when visiting the clinic after week 4 of the 
open melatonin treatment phase, or at the next evaluation 1 month later.
the postmelatonin high levels of salivary melatonin could be due to a 
supraphysiological dose of exogenous melatonin. However, the elimination half-
life of melatonin has been reported as 0.8 hours with an absorption half-life of 0.4 
hours, while melatonin levels ranged from 350 to 10 000 times those occurring 
physiologically (Waldhauser et al. 1984) Furthermore, in children 6–12 years of 
age who participated in a study using 5 mg of melatonin in a similar study design 
as in the present study, salivary melatonin levels measured 24 hours after the 
last exogenous melatonin intake, were normal and only showed a phase advance 
(Smits et al. 2001, 2003) If there were a large advance of the endogenous melatonin 
rhythm, so that endogenous melatonin started to increase largely before 5 PM, 
patients should have been sleepy in the afternoon. Parents did not report this. 
Another explanation for the high salivary melatonin levels approximately 24 hours 
after the last intake of melatonin is that the melatonin metabolism is disturbed in 
Angelman syndrome. Melatonin is metabolized in the liver by cytochrome P450 
1A2 to its main primary metabolite 6-hydroxymelatonin. Exogenous melatonin has 
a half-life between 30 and 50 minutes. Genetic variations influence the expression 
of specific cytochrome P450 isoenzymes in individuals and this finding influences 
their capacity to metabolize certain drugs (Claustrat et al. 2005). Assuming that 
exogenous melatonin does not stimulate endogenous melatonin secretion, it is 
likely that the high melatonin levels after 4 weeks of treatment with melatonin 
in 3 of 4 children in this study, found 24 hours after the last oral melatonin dose, 
were caused by a low activity of cytochrome P450 1A2 or another disturbance 
in the metabolism of melatonin. However, the possibility that the elevated 
levels were the result of down-regulation of endogenous melatonin or enzyme 
inhibition by anti-seizure medication can in some cases not be ruled out. Only 
3–4% of the white population is a poor metabolizer of cytochrome P450 1A2. that 
3 of 4 children with Angelman syndrome in the melatonin group had elevated 
melatonin levels after 4 weeks of treatment raises the question whether a low 
activity of cytochrome P450 1A2 is part of the Angelman syndrome phenotype.
We are studying the above-discussed explanations for a possible disturbed 
melatonin metabolism in Angelman syndrome patients. Until the results 
are published, we suggest testing melatonin metabolism in each individual 
Angelman syndrome patient before considering (long-term) melatonin treatment, 
for instance by measuring salivary melatonin hourly during 24 hours after 
melatonin administration. Consequently, the best pharmacotherapeutic dose can 
MELAtONIN tREAtMENt IN ANGELMAN SYNDROME
70
be determined, taking into account the individually measured elimination half-life 
of melatonin. If salivary melatonin levels do not reach basal values within 12 hours 
after melatonin administration, consider lowering the dose with at least 50%.
this first placebo-controlled study of melatonin in insomniac Angelman 
syndrome patients has several shortcomings. the number of patients (i.e., n = 8) 
was low. Many parents referred to our sleep clinic, when asked for permission to 
let their child participate in this study, refused to do so because they only wanted 
immediate help for their child’s problems instead of risking the possibility of 
another 4 weeks of disturbed sleep due to placebo treatment. In this study, 
sample size was very small and the power of the t-test was low. Despite low 
power, significant and meaningful differences were found between placebo 
and melatonin conditions. It should be noted that a randomized controlled trial 
with a larger sample size would have a larger statistical power. However, it is 
extremely difficult if not impossible to include a large number of participants 
with Angelman syndrome in any randomized controlled trial, because Angelman 
syndrome is a relatively rare genetic disorder.
We relied on parental sleep diaries rather than more objective measures, such 
as actigraphy. Melatonin levels would better have been measured more than 
24 hours, for example, 48 hours, after the last intake of exogenous melatonin. 
the sample was biased by referrals to a highly specialized outpatient clinic for 
insomniac patients with intellectual disabilities. these shortcomings threaten 
the validity of our conclusions. Nevertheless, the results show that melatonin 
treatment may help insomniac Angelman syndrome patients. However, further 
studies need to be performed on melatonin metabolism in Angelman syndrome 
to establish the best dose. this study indicates that it is possible that melatonin 
dose in Angelman syndrome should be lower than generally prescribed.
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chapter 5 
MELAtONIN DECREASES DAYtIME CHALLENGING 
BEHAVIOUR IN PERSONS WItH INtELLECtUAL DISABILItY 
AND CHRONIC INSOMNIA
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L.M.G. (2009). Melatonin decreases daytime challenging behaviour in persons 
with intellectual disability and chronic insomnia. Journal of Intellectual Disability 
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abstract
Background Persons with intellectual disability (ID) and sleep problems exhibit 
more daytime challenging behaviours than persons with ID without sleep 
problems. Several anecdotal reports suggest that melatonin is not only effective 
in the treatment of insomnia, but also decreases daytime challenging behaviour. 
However, the effect of melatonin treatment on daytime challenging behaviour 
in persons with ID has not been investigated in a randomized controlled trial.
Method We investigated the effects of melatonin on challenging behaviour using 
data from two randomized controlled trials on the efficacy of melatonin on sleep 
problems in 49 persons (25 men, 24 women; mean age 18.2 years, SD = 17.1) 
with ID and chronic insomnia. Participants received either melatonin 5 mg 
(<6 years 2.5 mg) or placebo during 4 weeks. Daytime challenging behaviour 
was measured by the Storend Gedragsschaal voor Zwakzinnigen – Maladaptive 
Behaviour Scale for the Mentally Retarded (SGZ; Kraijer & Kema, 1994) at 
baseline week and the end of the fourth treatment week. Salivary dim light 
melatonin onset (DLMO) was measured at baseline and the last day of the 
fourth treatment week. Sleep logs were used to gather information on sleep 
parameters.
Results Melatonin treatment significantly reduced SGZ scores, sleep latency, and 
number and duration of night wakes, and treatment increased total sleep time 
and advanced DLMO. However, after 4 weeks of treatment, change in SGZ 
scores did not significantly correlate with change in sleep parameters, nor with 
change in DLMO. Relatively strong correlations were found between change in 
SGZ scores, change in DLMO and number of night wakes.
Conclusions Melatonin treatment in persons with ID and chronic insomnia 
decreases daytime challenging behaviour, probably by improving sleep 
maintenance or by improving circadian melatonin rhythmicity.
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introduction
Sleep problems are more common in persons with intellectual disabilities (ID) than 
among the general population. Prevalence rates range from 15% to 88% depending 
on study design, participant characteristics and definition of sleep problems (Didden 
& Sigafoos 2001). Compared with persons with ID, but without sleep problems, 
persons with ID and sleep problems exhibit more daytime challenging behaviours, 
irritability and lethargy, and their ability to function optimally is diminished (Wiggs 
& Stores 1996; Chadwick et al. 2000; Didden et al. 2002).
the relationship between challenging behaviour and sleep problems is complex. 
Daytime challenging behaviour may both be a cause as well as a result of sleep 
problems, or be caused by a third independent variable (Didden et al. 2002).
Behavioural treatment can be effective in treating sleep problems in individuals 
with ID. However, evidence of a significant reduction in coexisting daytime 
challenging behaviour is lacking (Wiggs & Stores 1999; thackeray & Richdale 
2002). Melatonin improves sleep in patients with ID (Braam et al. 2009). there 
are several anecdotal reports suggesting that melatonin also decreases daytime 
challenging behaviour ( Jan et al. 1994; Jan 2000; Ivanenko et al. 2003; Coppola et 
al. 2004; Jan & Freeman 2004; Carr et al. 2007), but randomized controlled trials 
have not been published yet.
the aim of this study therefore was to investigate the effects of melatonin 
treatment on daytime challenging behaviour and to explore associations between 
daytime challenging behaviour, chronic insomnia and melatonin circadian 
rhythm in a sample of 49 persons with ID. For this purpose, we evaluated data 
in patients with ID with chronic insomnia who participated in two randomized 
controlled trials in which we measured sleep parameters, circadian melatonin 
rhythm and daytime challenging behaviour. the sleep data of these trials were 
published elsewhere (Braam et al. 2008-I; Braam et al. 2008-II).
the first hypothesis of the present study was that melatonin treatment would 
be more effective in reducing daytime challenging behaviour in persons with ID 
and chronic insomnia than placebo. the second hypothesis was that there would 
be a significant correlation between the presence and severity of challenging 
behaviour and the severity of sleep problems at baseline, as well as a significant 
correlation between changes in challenging behaviour and changes in sleep 
problems between baseline and the end of the treatment period.
Methods
Patients with ID and chronic insomnia were referred to our sleep center by local 
general practitioners and physicians for individuals with ID. Participants were 
included if no somatic and psychiatric causes for the insomnia were found, and 
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general behavioural treatment and sleep hygiene measures had been unsuccessful. 
Patients were included if they had: (1) sleep latency of 30 min or more; or (2) two 
or more wakes lasting more than 45 min each night; or (3) five or more wakes 
lasting more than 15 min each night, during at least five nights each week. 
Insomnia had to be present for the duration of at least 1 year. Exclusion criteria 
were prior use of melatonin, restless legs, sleep apnea syndrome, liver disease, 
renal failure, chronic pain and age younger than 24 months. the trial consisted 
of two consecutive periods: (1) a 1-week qualification period; and (2) 4 weeks of 
treatment during which participants were randomly allocated to melatonin or 
placebo conditions. All medications were held constant during all study phases. 
During the baseline week and consecutive treatment weeks caregivers completed 
daily a sleep log to assess sleep. to assess circadian melatonin rhythmicity (Lewy 
& Sack 1989), dim light melatonin onset (DLMO) was measured in saliva on the 
last night of the baseline week and on the last night of the last treatment week, as 
described by Nagtegaal et al. (1998).
the trial was performed in the home setting of each individual and was 
conducted according to the European Guidelines for Good Clinical Research 
Practice in Children (Committee for Proprietary Medicinal Products 1997) and 
followed the 1983revised provisions of the 1975 Declaration of Helsinki. the 
study was approved by the local Medical Ethical Committee. Written informed 
consent was obtained for all patients. Parents or other caregivers recorded lights 
off time, sleep latency, number and duration of night wakes, and wake up time 
in a sleep diary. Results on the efficacy of melatonin on insomnia were published 
previously (Braam et al. 2008-I; Braam et al. 2008-II). 
Treatment
During the 4-week treatment, patients aged 6 years and older daily received 5-
mg melatonin (Duchefa Farma BV, Haarlem, the Netherlands) mixed with 
carboxymethylcellulose in a fast release tablet, or an identically looking placebo, 
at 7 PM. A 5-mg dose was chosen because most placebo-controlled published 
trials with melatonin used this dose (see Dahlitz et al. 1991; Nagtegaal et al. 1998; 
Smits et al. 2001; Van Wieringen et al. 2001). Patients aged under 6 years received 
a daily dose of 2.5-mg melatonin at 6 PM. Compliance was tested by comparing 
the number of tablets returned with the number prescribed.
Daytime challenging behaviour
Parents or other caregivers completed the Storend Gedragsschaal voor 
Zwakzinnigen (SGZ; Maladaptive Behaviour Scale for the Mentally Retarded, 
Kraijer & Kema 1994) in the baseline week and at the end of the fourth treatment 
week, to assess daytime challenging behaviour. the SGZ is widely used in the 
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Netherlands and Dutch-speaking regions in Belgium. the scale consists of 32 
items, and factor analysis has yielded three sub-scales: (1) aggressive maladaptive 
behaviour (SGZ-A, maximum score of 72); (2) verbal aggressive behaviour (SGZ-V, 
maximum score of 28); and (3) mixed maladaptive behaviour (SGZ-M, maximum 
score of 160). the SGZ-A contains eight items on scratching, pinching, biting, 
pushing, hitting, kicking, spitting or pulling hair of parents, caregivers, siblings 
and/or other persons. the five items of the SGZ-V are on abusive language and 
nagging towards caregivers and/or other persons. the SGZ-M contains 19 items 
on self-injurious behaviour, stealing food, pica, tearing clothes, throwing or 
destroying objects, hyperactivity, screaming, nagging, noncompliance, public 
masturbating, faeces smearing and stereotyped behaviours. Each item is rated 
on a 4-point Likert-type scale, ranging from ‘0’ (behaviour did not occur) to ‘4’ 
(behaviour occurs at least 5 days per week). Scores are then multiplied by 2 or 
3, depending on the degree that the specific item is more or less disturbing to 
others. total scores on the three sub-scales are based upon summing up the 
scores of the sub-scale items. Scores from the three sub-scales may be summed 
to attain a total SGZ score (i.e. SGZ-t), which reflects the overall severity level of 
challenging behaviour (maximum score 260). the SGZ is validated for persons 
with ID, aged 3 years and over, and IQ 70 or less. the SGZ was found to satisfy 
the rigorous criteria used by the Dutch Psychological Association; its reliability 
and validity have been proven good (Evers 2001).
Outcome measures
Primary outcome measures were SGZ sub-scale and total scale scores, time lights 
went out, sleep latency, total sleep time, and number and duration of night wakes. 
Secondary outcome measure was DLMO to assess circadian rhythmicity (Lewy 
& Sack 1989). DLMO was defined as the first time at which salivary melatonin 
reached 4 pg/mL (Nagtegaal et al. 1998), and is the most reliable marker of circadian 
phase position (Lewy et al. 1999; Pandi- Perumal et al. 2007). Statistical analyses 
Independent samples t-tests were used to test whether there were differences in 
age and outcome measures between the melatonin and placebo group at baseline. 
T-tests for independent samples were also conducted to test differences in change 
between melatonin versus placebo treatment on the SGZ scores, DLMO and sleep 
parameters. In cases where equal variances could not be assumed (tested with 
Levene’s test), results of t-tests with adjusted degrees of freedom are reported. 
General Linear Modelling (GLM) analysis corroborated the findings of the t-tests. 
Relationships between SGZ scores, DLMO and sleep variables were explored 
using Pearson’s correlation coefficient. A χ2-test was conducted to control if the 
melatonin and placebo groups differed in degree of ID. Statistical significance 
was accepted at P < 0.05.
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results
Sixty-six children and adults with ID and chronic insomnia were randomly assigned 
to melatonin or placebo conditions (Fig. 1). During the baseline week parents of 
one child withdrew informed consent because their child refused to cooperate with 
saliva sampling. Nine individuals in the placebo group and seven in the melatonin 
Figure 1: Trial profile.Trial A: Braam et al. (2008a); trial B: Braam et al. (2008b).
Patients randomized
(n = 66)
[n = 58 (trial A) + n = 8 (trial B)]
Melatonin Placebo
(n  = 34) (n = 32)
Informed consent withdrawn
(n = 1)
Insufficient data on sleep Insufficient data on sleep
(n  = 1) (n = 5)
Insufficient data on behavior Insufficient data on behavior
Melatonin Placebo
(n  = 33) (n = 26)
(n  = 27) (n = 22)
(n  = 6) (n = 4)
Melatonin Placebo
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group were excluded because parents or other caregivers did not complete the sleep 
log or SGZ scale.
the melatonin group consisted of 27 patients (16 men, 11 women), aged 4–78 
years (mean age 18.8 years, SD = 18.0), of whom 21 (67%) were 13 years or younger 
and 12 (33%) were 20 years or older. the degree of ID was profound (n = 11), severe 
(n = 9), moderate (n = 3) and mild (n = 4).
the placebo group consisted of 22 patients (9 men, 13 women), aged 2–58 years 
(mean age 17.5 years, SD = 16.5), of whom 16 (68%) were 14 years or younger and 10 
(32%) were 20 years or older. the degree of ID was profound (n = 9), severe (n = 4), 
moderate (n = 3) and mild (n = 6). Mean baseline SGZ scores, sleep parameters and 
DLMO did not significantly differ between melatonin and placebo groups (table 1). 
Mean age did not significantly differ between the melatonin and the placebo groups 
[t (47) = 0.27, P = 0.79], as well as degree of ID [χ2 (3) = 2.03, P = 0.62].
Compared with placebo, melatonin treatment significantly reduced mean SGZ-
t and SGZ-M scores, but scores on the SGZ-V sub-scale remained unchanged. 
Although some items of the SGZ-A sub-scale showed a clinical improvement, 
mean SGZ-A score did not decrease significantly (P = 0.076) (table 1). SGZ items 
that showed a significant reduction (P < 0.05) were hitting/kicking of parents/
caregivers [M
melatonin
 = -0.33, SD
melatonin
 = 0.68; M
placebo
 = 0.00, SD
placebo
 = 0.00; t (26) 
= 2.55, P = 0.017], hitting/kicking of others [M
melatonin
 = -0.26, SD
melatonin
 = 0.53; 
M
placebo
 = 0.05, Sd
placebo
 = 0.21; t (35.75) = 2.75, P = 0.009] and destroying objects 
[M
melatonin
 = -0.63, SD
melatonin
 = 1.12; M
placebo
 = -0.09, SD
placebo
 = 0.29; t (30.36) = 2.41, 
P = 0.022]. 
Mean sleep latency, mean duration of wakes and mean number of nights with 
wakes per week decreased during melatonin treatment more than during placebo 
treatment (mean of the difference was 34 min, 9 min and 0.66 respectively). Mean 
total sleep time increased during melatonin treatment 34 min more than during 
placebo, while mean DLMO advanced significantly 1:57 h more. time patients 
went into bed, as well as time they woke up, did not differ significantly between 
baseline and the end of the fourth treatment week. So increase in total sleep time 
could be contributed mostly to the reduction of sleep latency and the reduction in 
number and duration of night wakes. 
Relationship between age and Storend Gedragsschaal voor Zwakzinnigen, sleep 
parameters and dim light melatonin onset 
At baseline there were significant correlations between age and SGZ-A scores (r = 
-0.37, P = 0.009), SGZ-t scores (r = -0.30, P = 0.037), DLMO (r = 0.34, P = 0.023), 
time lights out (r = 0.60, P ≤ 0.001) and total sleep time (r = -0.36, P = 0.018). 
However, after 4 weeks of treatment no significant correlations between age and 
change in SGZ-t, sleep parameters or DLMO in the melatonin group were found. 
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Relationship between Storend Gedragsschaal voor Zwakzinnigen and sleep parameters 
and dim light melatonin onset 
At baseline there were no significant correlations between SGZ-t scores, DLMO 
and sleep parameters except for a negative correlation between SGZ-t scores and 
time lights went out at bedtime (r = -0.37, P = 0.017). After 4 weeks of melatonin 
treatment, change in SGZ-t scores did not correlate significantly with change in 
DLMO, nor with change in any of the sleep parameters (table 2).
discussion
Four weeks of treatment with melatonin in patients with ID with chronic insomnia 
was more effective in reducing challenging behaviour and sleep problems than 
placebo. Challenging behaviour was more prominent in children than adults, 
but effectiveness of melatonin treatment (in terms of difference scores) did not 
correlate with age. Other correlations with age at baseline were to be expected, as 
DLMO and sleep variables are age-related in non-disabled persons. 
this is the first randomized study to support clinical experience ( Jan et al. 
1994; Jan 2000; Ivanenko et al. 2003; Coppola et al. 2004; Jan & Freeman 2004; 
Carr et al. 2007) that melatonin treatment not only improves sleep, but also reduces 
daytime challenging behaviour in persons with ID with chronic insomnia. 
these findings are in agreement with two other studies showing that melatonin 
improves daytime functioning: (1) a study in patients with neurodevelopmental 
disorders in which slow release melatonin improved sleep and caregiver ratings of 
global functioning (Wasdell et al. 2008); and (2) a study in children with chronic 
sleep onset insomnia and late DLMO in which melatonin improved sleep and 
health status (Smits et al. 2003). 
Table 2: Correlations between change in SGZ-T scores and change 
in DLMO and sleep parameters after 4 weeks of melatonin treatment
Change in SGZ-T scores
Change in: n r p
DLMO 23 -.35 .104
Sleep latency 27 -.07 .733
Nights with wakes / week 23 .35 .103
Total sleep 23 .02 .936
DLMO, dim light melatonin onset; SGZ-T, total Storend Gedragsschaal 
voor Zwakzinnigen score.
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Reduction of daytime challenging behaviour after effective treatment of 
disordered sleep in persons with ID is generally assumed to be caused by the 
improvement of sleep. However, in the present study presence and severity 
of challenging behaviour did not correlate with severity of sleep problems at 
baseline, nor did we find significant correlations between change in SGZ scores 
and improvement in sleep at the end of the treatment period. Patients with severe 
sleep problems did not show more challenging behaviours than patients with 
milder sleep problems. And patients that showed a larger reduction of sleep 
problems after 4 weeks of treatment did not show a larger reduction of daytime 
challenging behaviour either. 
Although the correlation coefficients between change in SGZ-t scores and 
change in number of nights with wakes per week and with change in DLMO were 
not statistically significant, the relative strong correlations between both (>0.30) 
may be of interest (table 2). It is plausible that the reduction of daytime challenging 
behaviour is not caused by one single factor, such as the improvement of sleep (i.e. 
reduced sleep latency and increased total sleep time), but also by the correction of a 
disturbed melatonin circadian rhythm, as a second variable. the relation between 
change in SGZ-t scores and change in DLMO, respectively, number of nights 
with wakes per week points in this direction. Melatonin is a chronobiotic drug 
with some hypnotic properties (Wirz-Justice & Armstrong 1996). therefore, it is 
plausible that the reduction of daytime challenging behaviour could be attributed 
to the chronobiotic action of melatonin. this also implies that it is possible that 
daytime challenging behaviours in our patients with ID not only were caused by 
poor sleep maintenance, but more or less also were related to a misalignment or 
other disturbance of the circadian melatonin rhythm. 
One other possibility needs consideration, that is, a direct influence of 
melatonin on mood as a possible underlying cofactor causing problem behaviour. 
Sleep–wake disorders are frequently seen in persons with affective and depressive 
disorders. they may provoke manic episodes and can act as an independent risk 
factor for depression recurrence. this means that circadian sleep–wake rhythm 
dysfunction can play an aetiological role rather than being the result of psychiatric 
disorders (Leibenluft 2008). Maybe melatonin reduces daytime challenging 
behaviour indirectly by influencing mood. 
the timing of the administration of melatonin is very important in its efficacy. 
We administered melatonin at a fixed time. Consequently, an age-dependent 
treatment effect could be expected. However, we could not demonstrate this, 
probably because the number of patients was too small and the measurements 
of treatment effects too rough. Although SGZ, DMLO and sleep parameters were 
not significantly different between the melatonin and placebo groups at baseline, 
there were age differences and differences in severity within the groups. However, 
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we controlled for these differences analyzing the treatment effects and found no 
influence at the outcome measures. 
Some limitations of the present study need consideration. First, we pooled 
data of two studies (Braam et al. 2008-I; Braam et al. 2008-II). However, both had 
the same study design and were performed at the same time window. A second 
limitation is that we used diaries to measure sleep. Diary measures obviously have 
measurement errors, but are frequently used in non-clinical settings. However, 
the measurement error is the same for treatment and placebo. Sleep diaries based 
on observations by others yield more satisfactory data than sleep diaries based on 
self-report (Ancoli-Israel et al. 2003). Besides, parents of sleep-disturbed infants 
have been shown to be accurate reporters of actigraphically assessed sleep onset 
and sleep duration (Sadeh et al. 1991). therefore, we think that diary measures 
based on observations by parents and other caregivers can be used in assessing 
sleep parameters. 
We included only participants that fulfilled strict criteria for duration and 
severity of their sleep problems. Next to this, for participants to be included both 
sleep hygiene measures and behavioural approaches had been implemented but 
remained unsuccessful in decreasing their sleep problems. Future studies should 
assess generality of our conclusions. In this study also sleep efficacy could be taken 
into account. We failed to measure sleep efficiency, for example, by using actigraphy. 
In our clinical study, we could not calculate sleep efficiency because parents only 
recorded the time their child woke up but failed to record the time their child went 
out of his/her bed. As a result, sleep efficiency could not be calculated.
conclusions
Results of our study suggest that melatonin treatment can be effective in patients 
with ID with daytime challenging behaviour and chronic insomnia. Further 
studies are needed to confirm these findings.
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abstract
Background In some of our patients with intellectual disability (ID) and sleep 
problems, the initial good response to melatonin disappeared within a few 
weeks after starting treatment, while the good response returned only after 
considerable dose reduction. the cause for this loss of response to melatonin is 
yet unknown. We hypothesize that this loss of response is associated with slow 
melatonin metabolism. 
Method In this study we determined melatonin clearance in two female (aged 
61 and 6 yr.) and one male (aged 3 yr.) patients who had chronic insomnia, 
late melatonin onset and mild ID, and whose sleep quality worsened a few 
weeks after initial good response to melatonin treatment, suggesting melatonin 
tolerance. After a 3 week washout period, patients received melatonin 1.0, 0.5 or 
0.1 mg respectively. Salivary melatonin level was measured just before melatonin 
administration, and 2 and 4 hours thereafter. After this melatonin clearance 
test, melatonin treatment was resumed with a considerably lower dose. 
Results In all patients melatonin concentrations remained >50 pg/ml at 2 and 
4 hours after melatonin administration. After resuming melatonin treatment 
sleep problems disappeared. the same procedure was followed in 3 patients 
who did not show loss of response to melatonin after 6 months of treatment. In 
all patients in the control group melatonin concentrations decreased between 2 
and 4 hours after melatonin administration with a mean of 83%. 
Conclusion We hypothesize that loss of response to melatonin treatment can 
be caused by slow metabolization of exogenous melatonin. As melatonin 
is metabolized in the liver almost exclusively by cytochrome P450 enzyme 
CYP1A2, this slow melatonin metabolism is probably due to decreased activity/
inducibility of CYP1A2. In patients with loss of response to melatonin, a 
melatonin clearance test should be considered and a considerably dose reduction 
is advised.
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introduction
In our double-blind, placebo-controlled, parallel study in children with Angelman 
syndrome, some parents reported loss of response (i.e. return of night wakes) 
after 4 weeks of melatonin (5.0 mg ≥ 6 year and 2.5 mg < 6 year) treatment (Braam 
et al. 2008). Evening salivary melatonin levels were measured at baseline and 
after 4 weeks of treatment on a day no study medication was given. Melatonin 
levels in 3 of the 4 patients who received melatonin, were extremely high (>50 pg/
ml) after 4 weeks of treatment, while they were very low at baseline. In response 
to these high levels we lowered the melatonin dose to 0.1mg, which resulted 
in substantially improved sleep. We postulated that these patients with loss of 
response to melatonin treatment, possibly as a result of enduring high melatonin 
levels, were CYP1A2 poor metabolizers.
From that time we have seen several patients with an intellectual disability 
(ID) who responded initially well on melatonin in the adequately timed dose (3-5 
mg in adults and 1-2.5 mg in children aged 5-12 yr). the initial good response 
disappeared after a few weeks of treatment, but returned when the dose was lowered 
considerably ( 0.1 – 0.5 mg), while time of administration did not change.
Exogenous melatonin is a chronobiotic drug with some hypnotic properties 
(Zhdanova et al.1997). It advances sleep onset in adults (Nagtegaal et al. 1998) 
and children (Smits et al. 2003; Van der Heijden et al. 2007) with chronic sleep 
onset insomnia and late endogenous dim light melatonin onset (DLMO), and it 
improves sleep in patients with ID (Braam et al. 2009). Melatonin advances sleep-
wake and other circadian rhythms maximally in adults when it is administered 5 
to 6 hours before DLMO (Lewy et al. 1992), while soporific effects occur within 30 
to 60 minutes after intake (Zhdanova 2005).
the effective dose of melatonin still remains a matter of discussion. When 
the dose is too low, melatonin does not influence circadian rhythmicity. When 
the dose is too high melatonin does not work anymore because melatonin levels 
remain high and lose rhythmicity (Lewy et al. 2005). Dollins et al. (1994), in a study 
comparing the effects of a wide range of melatonin doses (0.1 – 10 mg), reported 
that the efficacy of low (0.1 – 0.3 mg) ‘physiological doses’ (i.e. doses resulting 
in serum melatonin levels within normal nocturnal range), did not significantly 
differ from the efficacy of pharmacological doses (1.0 – 10 mg) in promoting 
sleep when administered during the day to young healthy subjects. According 
to Zhdanova (2005) doses to induce physiologic circulating melatonin levels (0.1 
– 0.5 mg) are sufficient to promote sleep and to induce circadian phase shift, 
whereas too high doses may cause side effects, i.e. circadian rhythm alterations 
and possibly desensitize melatonin receptors. 
Melatonin is metabolized in the liver almost exclusively by cytochrome P450 
enzyme CYP1A2 to its main primary metabolite 6-hydroxymelatonin, than 
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conjugated to sulphate, and excreted in urine (Claustrat et al. 2005). In most 
individuals exogenous melatonin has a half-life between 35 and 45 minutes 
(Fourtillan et al. 2000). Caffeine clearance is considered as the gold standard 
for assessment of the CYP1A2 activity, because more than 90% of the primary 
metabolism of caffeine depends on CYP1A2 (Härtter et al. 2006). However, as 
melatonin is metabolized more exclusively by CYP1A2, melatonin has been 
proposed as an alternative probe drug for CYP1A2 activity (Härtter et al. 2001).
there are large inter-individual differences in plasma levels after oral 
administration of melatonin as high as 37-fold, as well as a 2.5-fold difference in 
bioavailability of melatonin between females and males. these differences can be 
attributed to inter-individual variation of the first-pass effect through the liver and 
the activity of gastrointestinal CYP (Fourtillan et al. 2000). 
Reports on loss of response, after initial good response to melatonin treatment 
are scarce, and in some reports the development of tolerance to melatonin was 
suggested, because sleep improved temporary when increasing the melatonin 
dose. We hypothesize that, what we call loss of response to melatonin treatment 
can be explained by slow metabolism of melatonin, resulting in such an increase of 
melatonin levels that melatonin rhythmicity disappears. Consequently melatonin 
loses its chronobiotic and hypnotic effects. therefore the melatonin dose has to 
be reduced instead of being increased. to evaluate this hypothesis, we studied 
melatonin metabolism in three patients showing loss of response to melatonin 
treatment, and in three patients that did not show signs of loss of response after 
6 months of melatonin use. 
Methods
We studied three patients with loss of response to melatonin treatment, i.e. patients 
who initially responded very well to melatonin therapy, but in whom this effect was 
lost after several weeks of therapy and sleep problems eventually became worse 
than before therapy started. they visited our expert center for patients with sleep 
disturbances and ID. In these patients parents and other caregivers completed 
daily a sleep log to assess sleep. the rate of melatonin metabolization was assessed 
with a clearance test. At 11 a.m., 1 p.m. and 3 p.m. saliva samples were collected in 
Salivette® tubes (Sarstedt, Nümbrecht, Germany) by chewing on a cotton swab for 
1-2 minutes. Immediately after the first sample collection melatonin (1mg, 0.5 mg 
or 0.1 mg respectively) was taken. Melatonin levels were measured in saliva with a 
Radio Immuno Assay (RIA) (Buhlmann laboratories, Schönenbuch, Switzerland) 
as previous described (Nagtegaal et al. 1998). Radio activity was counted with 
the PerkinElmer 1470 Wizard gamma counter (PerkinElmer Nederland B.V., 
Groningen, the Netherlands). the linear range is between 0.5 and 50 pg/ml. When 
CHAPtER 6
91
exceeding the linear range the samples were diluted, provided that there was 
sufficient sample amount. 
From the time we became aware of possible slow melatonin metabolism, we 
perform the melatonin clearance test in all patients who are going to be treated 
with melatonin. Patients who did not show loss of response to melatonin after 
6 months of treatment were considered normal melatonin metabolizers. Initial 
data from three patients, who did not show signs of loss of response to melatonin 
after 6 months of treatment, were used as controls in this study.
results 
Case 1
Case 1 is a 61 year old woman with a mild ID, for which no cause had been 
identified, who was admitted to our sleep clinic because of severe sleep onset 
problems. She lived in a group home for over 20 years and had never been able to 
fall asleep before 1 AM In the morning however, she was sleepy when she had to get 
up at 8 AM there were no physical problems that could account for her sleep onset 
problems. She suffered from epilepsy which was treated by carbamazepine (800 
mg), lamotrigine (200 mg) and phenobarbital (35 mg). Despite this medication, 
she had a generalized epileptic attack two or three times a year on average.
DLMO occurred at 10:58 pm (table 1), consistent with a delayed sleep phase 
syndrome. She was prescribed 5 mg melatonin at 9 PM, the usual time evening 
medication was given by her caregivers. She was advised to go to bed at 10 PM, 
but she refused to do so as this would result in a major change in her lifestyle. So 
we compromised at 11 PM and to go to bed at midnight. two weeks later she told 
us that she was very satisfied with the result. She now took her melatonin at 10 
PM and fell asleep before 11 PM Moreover, she told, she felt no longer sleepy the 
next morning.
three months later she returned to our sleep clinic, complaining that since 
4 weeks “her sleeping pill did not work anymore”. She told us that she could 
not fall asleep before 0:30 AM and felt sleepy again in the morning. A caregiver 
accompanying her, informed us that she was very irritable and had mood swings 
at daytime.
the results of the melatonin measurements are summarized in table 1. 
Melatonin levels at the end of the evening, on an evening we asked her to take no 
melatonin, and in the middle of the next day, were > 50 pg/ ml. the melatonin 
clearance test, using 1 mg melatonin, performed three weeks after stopping the 
melatonin treatment, showed that salivary melatonin concentration remained 
> 50 pg/ml during 6 hours after administration of melatonin (table 2; Fig. 1). 
We concluded that she was CYP1A2 poor metabolizer. therefore we lowered the 
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Figure 1: Melatonin clearance test in Case 1 and control. Melatonin in saliva before and after 
1mg melatonin at 11:00 AM.
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Figure 2: Melatonin clearance test in Case 2 and control. Melatonin in saliva before and after
0,5mg melatonin at 11:00 AM.
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Figure 3: Melatonin clearance test in Case 3 and control. Melatonin in saliva before and after 
0,1mg melatonin at 11:00 AM.
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figure 1: Melatonin clearance test in Case 1 and control. Melatonin in saliva before and 
after 1mg melatonin at 11:00 AM.
figure 2: Melatonin clearance test in Case 2 and control. Melatonin in saliva before and 
after 0,5mg melatonin at 11:00 AM.
figure 3: Melatonin clearance test in Case 3 and control. Melatonin in saliva before and 
after 0,1mg melatonin at 11:00 AM.
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melatonin dose to 0.5 mg. As a result her sleep onset problems disappeared, as 
did her complaints about feeling sleepy in the morning. Her irritability and mood 
swings also had disappeared. Six months later positive effect of melatonin was 
still present with 0.5 mg melatonin at 10 PM.
Case 2
Case 2 is a 6 year old girl, who was referred to our sleep center because of sleep 
onset and sleep maintenance problems, that existed for several years. She had a 
mild ID, for what a comprehensive genetic examination had not revealed a cause. 
She was put to bed at 8:30 PM and could only fall asleep when her mother was 
sitting at her bedside. Even then it took over one hour for her to fall asleep. One or 
two times every night she went to her mother’s bedroom and tried to get into her 
bed. Her mother had to force her to go back to her own bed, and it took another 
hour to put her back to sleep. 
At admission, DLMO occurred at 9:18 p.m. (table 1). Melatonin 2.5 mg was 
administered at 7:30 PM. Four weeks after start of melatonin treatment, her 
mother informed us that she was very satisfied with the results. Her daughter 
became sleepy within half an hour after taking melatonin and fell asleep before 
8:30 PM. Only two or three nights a week she went to her mother’s bed in the 
middle of the night, but could easily be brought back to her own bed. At daytime 
she played with more concentration and was not hyperactive anymore.
One month later, however, her mother complained that her daughter’s sleep 
maintenance problems had slowly returned. She even woke up more often during 
the night, and earlier in the morning, than before melatonin treatment. Also, sleep 
latency had become longer and at daytime she again showed hyperactive behaviours. 
Her mother had doubled melatonin dose on her own initiative, because she thought 
her daughter had developed tolerance to the treatment, but this failed to have an 
effect on her daughter’s sleep problems. Salivary melatonin levels during the day 
and night were all > 50 pg/ml, on a day no exogenous melatonin was taken (table 
1). After a wash-out period of 2 weeks, the melatonin clearance test showed that 
salivary melatonin levels remained > 50 pg/ml during 6 hours after administration 
of melatonin 0.5 mg (table 2; Fig. 2). therefore we concluded that she was CYP1A2 
poor metabolizer. Melatonin treatment was resumed with 0.5 mg at 8:30 PM. 
this resulted in advancement of sleep onset and better sleep maintenance. Her 
mother told that she had not slept as well as now since many years. She also was not 
hyperactive anymore. these positive effects were still present 6 months later.
Case 3
Case 3 is a 3-year old boy with Down syndrome, who attended the sleep center 
because of sleep maintenance problems and early waking since one year. He also 
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had settling problems since his mother had stopped breastfeeding when he was 6 
months old. He could only fall asleep when in the arms of his mother. Because of 
recommendations of friends, who also had a disabled child, his mother had asked 
her general practitioner for a melatonin prescription. Melatonin 1 mg had an 
instant success. Unfortunately, frequent night wakes returned after four weeks, 
and the boy’s parents stopped giving him melatonin. But because he did not fall 
asleep before 10 PM, parents started to give him melatonin again, in spite of the 
sleep maintenance worsening. At our sleep center we saw a hyperactive boy with 
Down syndrome. We advised to stop melatonin medication, and asked parents 
to take salivary samples. two days after discontinuing melatonin treatment, 
melatonin levels were >50 pg/ml at noon as well as in the afternoon and evening 
(table 1). two weeks later, without melatonin, parents told that night wakes had 
Table 1: Melatonin (pg/ml) in saliva before treatment start 
and during treatment when response was lost.
Case 1 Case 2 Case 3
6:00 PM <0.5 *
7:00 PM <0.5 *
8:00 PM # *
9:00 PM 2.6 2.0 *
10:00 PM 1.1 8.8 *
11:00 PM 4.1
12:00 AM 5.1
1:00 AM 7.6
DLMO 10:58 PM 9:18 PM *
Case 1 Case 2 Case 3
12:00 PM >50.0 >50.0 >50
4:00 PM >50.0 >50.0 #
6:00 PM >50.0 >50
7:00 PM >50.0 >50
8:00 PM >50.0 >50
9:00 PM >50.0 >50.0 >50
10:00 PM >50.0 >50.0 #
11:00 PM >50.0
12:00 AM >50.0
1:00 AM >50.0
* No melatonin levels measured prior to start melatonin treatment.
# Not enough saliva collected for assessment melatonin levels.
Prior to treatment start
After loss of response
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disappeared, but that sleep onset problems still existed. At that time melatonin 
levels had returned to normal low levels. the melatonin clearance test, performed 
3 days later, using 0.1 mg melatonin, showed that salivary melatonin levels 
remained > 50 pg/ml during 6 hours after administration of melatonin (table 2; 
Fig. 3). therefore we concluded that he was CYP1A2 poor metabolizer.
two weeks later sleep latency became longer than 2 hours and parents asked 
for medication. We resumed melatonin in a lower dose (0.1 mg). As a result of 
this, sleep latency was reduced to 15 minutes or shorter. Only once a week their 
son woke up in the middle of the night, but could be brought back to his bed 
easily. At follow up 6 months later, these results were still preserved.
Control subjects
three patients that visited our sleep center, aged 40, 12 and 8 years of age 
respectively, that did not show signs of loss of response to melatonin treatment 
after 6 months of treatment, served as control patients. their melatonin clearance 
tests prior to the start of the melatonin treatment, showed a normal profile with a 
mean 83% decline in melatonin levels. Half-life of melatonin was 44, 46 and <50 
minutes respectively (table 2).
discussion
Melatonin metabolism was measured in three ID patients that showed a 
remarkable return of sleep problems after an initial about 4-weeks lasting good 
response to melatonin treatment. In these patients sleep improved again after 
lowering the melatonin dose considerably. the melatonin clearance test in these 
three patients showed very high levels of melatonin even 6 hours after intake of 
melatonin, supporting the view that exogenous melatonin was metabolized much 
slower than in control patients who remained good melatonin responders during 
Table 2: Melatonin clearance test in Case 1, 2 and 3 and in 3 control patients
Case 1 Case 2 Case 3 Control 1 Control 2 Control 3
Melatonin dose 1 mg 0.5 mg 0.1 mg 1 mg 0.5 mg 0.5 mg
Melatonin (pg/ml) in saliva
11:00 AM 5.1 5.0 3,4 2,7 0,5 0,4
1:00 PM >50.0 >50.0 >50 49,1 15,3 >100
3:00 PM >50.0 >50.0 >50 7,6 2,6 19,6
Melatonin half time (min) # # # 44 46 <50
#  T½ can not be determined
Melatonin clearance test
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at least 6 months of melatonin treatment. therefore we concluded that these three 
patients are CYP1A2 poor metabolizers. 
For CYP1A2, metabolism of most substrates can be described using the 
Michaelis-Menten equation, demonstrating saturation kinetics. For some 
substrates in higher concentration the model seems inadequate, suggestive of a 
two binding sites model, either inhibitory or cooperative (Miller & Guengerich 
2001; Lin 2001). Saturation will fortify the effects of exogenous melatonin in 
poor metabolizers. Poor metabolizers will initially experience disproportional 
long lasting higher serum levels after normal doses resulting in effective therapy. 
During the first stage of saturation they will experience disproportional increase 
in serum levels after a normal dose, thus still resulting in effective therapy. Finally 
such a high level will be reached, that a next dose won’t result in an effective 
increase of serum level. this could be the explanation for delayed onset of these 
effects and the huge impact of dosage reduction. the delay in the loss of response 
to melatonin treatment and the effectiveness of dose reduction with restoration 
of rhythmicity can be attributed to the saturation phenomenon, with eventually 
much extended elimination half life values for melatonin.
Several reports indicate that single nucleotide polymorphisms in the CYP1A2 
gene are associated with increased inducibility, decreased activity or inducibility 
or even loss of activity of the CYP1A2 enzyme as compared tot the wild type 
(Sachse et al. 1999; Nakajima et al. 1999; Chevalier et al. 2001; Zhou et al. 2009-I; 
Zhou et al. 2009-II). the (sub)variant alleles associated with decreased of absent 
activity of CYP1A2 are *1C, *1K, *3, *4, *5, *6 and *7.the CYP1A2 locus is found 
on chromosome 15q24.1 (NCBI 2010). the proportion of individuals with the 
slow phenotype narrowly ranges from 12 – 14% (Butler et al. 1992; Nakajima et al. 
1994), but varies among ethnic populations (Zhou et al. 2009-I). 
As far as we know this is the first study on the association between loss of 
response to melatonin treatment, and slow metabolization of melatonin. Until 
now, there are only a few anecdotal reports that melatonin can lose its effect 
during long term use, all in ID persons. McArthur & Budden (1998), in a double-
blind, placebo-controlled, crossover study in 9 children (age 4 - 17 years) with Rett 
syndrome, found melatonin (2.5 - 7.5 mg depending on age and body weight) 
to be effective in reducing sleep latency during the first 3 weeks of the study. 
However, this positive effect was lost in the fourth treatment week, when mean 
sleep latency became even worse than with placebo. Also Ishizaki et al. (1999), in 
a study on 50 children and young adults with ID, reported that in some cases the 
effectiveness of melatonin was diminished in the course of the study. Jan et al. 
(2000), in a study to examine effective doses of controlled-release melatonin in 42 
children with chronic sleep–wake cycle disorders and severe neurodevelopmental 
difficulties, reported that 4 children developed tolerance to the treatment, but that 
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this was difficult to prove because in patients with neurodevelopmental disorders 
other unrecognized causes of sleep disturbance can emerge, incorrectly suggesting 
tolerance. Andersen et al. (2008), in a retrospective study on 107 children with 
autism spectrum disorders that were prescribed melatonin for insomnia, found 7 
cases in which sleep initially improved, but sleep problems returned, despite dose 
escalation. In these four studies, however, possible causes were not studied. In 
some reported cases of loss of response to melatonin treatment the development 
of tolerance to melatonin was suggested, because sleep improved temporarily 
when increasing the melatonin dose. Results from our study, however, show that 
loss of response to melatonin treatment is not caused by melatonin tolerance, but 
by slow metabolizing of melatonin. In tolerance (also called tachyphylaxis, i.e. 
with nitrates) there is a diminution of the response to a drug after continued use, 
necessitating larger doses to restore the response. Wearing-off is normally spoken 
used in context of end of dose phenomenon: e.g. in Parkinson’s disease, prior 
to the next dose of levodopa. In the last hours before the next dose of levodopa, 
especially the kinetic symptoms of Parkinson worsen seriously. In our patients, 
however, a lasting melatonin effect only returned after lowering of the dose; 
therefore we probably best describe this observation as loss of response. 
Results from this study indicate that loss of response to melatonin treatment 
is associated with slow melatonin metabolization. this may result in increasing 
daily melatonin levels. Consequently after some time this will lead to highly 
cumulated melatonin levels and the circadian melatonin rhythm is lost. this loss 
of circadian rhythm might explain why exogenous melatonin in our cases lost its 
effectiveness. Lewy et al. (2002), describing a blind patient with a free-running 
circadian rhythm, who could be entrained to 0.5 mg of melatonin but not to 20 
mg, was the first who showed that melatonin loses its chronobiotic activity when 
the dose is too high.
there are several other possible causes of the loss of response to melatonin 
treatment. When the patients do not take melatonin the treatment will not 
be effective. therefore we always ask parents to be sure that their child takes 
melatonin indeed. the timing of melatonin administration is very important. 
to advance sleep-wake rhythm and consequently advance sleep onset, melatonin 
should be administered 5-6 hours before DLMO in adults (Lewy et al. 2002; 
Van Der Heijden et al. 2005). Melatonin advances the DLMO. When melatonin 
is administered close to the DLMO, DLMO cannot be advanced. Consequently 
melatonin loses its chronobiotic activity. In that case exogenous melatonin should 
be administered earlier. In case 1 melatonin was administered about 2 hours 
before DLMO. therefore it cannot be ruled out that exogenous melatonin lost 
its effectiveness because it was administered too close to the advanced DLMO. 
Another explanation could be a probable desensitization of melatonin receptors 
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during prolonged elevation of circulating melatonin to supraphysiologic levels, as 
was suggested earlier by Zhdanova (2005). However, the results of the melatonin 
clearance test and the improvement of the sleep after considerably lowering the 
melatonin dose strongly suggest that the increased melatonin levels, due to the 
slow metabolization of melatonin, were the main cause of the recurrence of the 
sleep problems in our cases
Some limitations of this study need consideration. First, we only studied three 
patients and three controls. However our robust results can be explained by a clear 
well funded theory. Furthermore, the time at which melatonin was admitted needs 
discussion. this time was not in accordance with usual recommendations i.e. 5 
hours before DLMO in adults (Pandi-Perumal et al. 2007). However in children 
the optimal time of melatonin administration has not yet been established. 
the results of the melatonin clearance test and the improvement of the sleep 
after considerably lowering the melatonin dose strongly suggest that the slow 
metabolization of melatonin was the main cause of the recurrence of the sleep 
problems, and not the time of administration. And lastly, our patients had mild 
ID. However, to our knowledge, there are no reports on altered pharmacokinetics 
of melatonin in individuals with an ID. 
In many cases melatonin is prescribed by non-melatonin specialized family 
physicians. Observations like described above will be attributed to inadequate 
dosing and wrongly lead to dose escalation. Experience with the relationship 
of medication timing with DLMO and the awareness of the complicated 
pharmacokinetics are required for appropriate evaluation of therapy. therefore 
melatonin therapy should be initiated and initially be controlled by experienced 
sleep professionals. this way only we can extend effectively our knowledge of 
this chronobiotic, and prevent negative experiences and resulting prejudices. 
Melatonin is in several countries available as an over-the-counter drug. A 
considerable number of people are CYP1A2 poor metabolizer and unaware of 
this. these circumstances are strong arguments for the need of further research 
to verify our findings. 
Based on the results of this study we are performing melatonin clearance tests 
in all patients who are going to be treated with melatonin. Furthermore we study 
CYP1A2 polymorphisms in all these patients. When the clinically relevant slow 
melatonin metabolization phenotypes can be associated with polymorphisms of 
the CYP1A2 gene, it will be possible to determine the optimal melatonin dose 
individually by genotyping CYP1A2 alone (without the melatonin challenge). We 
already knew that the timing of melatonin should be individually determined by 
the individual DLMO (Van Der Heijden et al. 2005). the present study shows that 
also the appropriate dose probably should be individually determined, by any means 
for a substantial part of the population with above described polymorphisms. We 
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expect to be able to determine CYP1A2 status in the same saliva samples as in 
which DLMO is measured, this makes it possible to individualize timing and 
dose of melatonin easily. 
Pending the results of future studies on the significance of melatonin 
metabolization, clinicians who treat patients with melatonin should be aware 
of the possibility of slow melatonin metabolization. When it is not possible to 
perform a melatonin clearance test, it is strongly advised to lower the melatonin 
dose instead of increasing the melatonin dose, in case melatonin treatment 
effectiveness decreases considerably after an initially few weeks lasting good 
response to melatonin treatment. 
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introduction
the main conclusion of our studies is that melatonin is effective in the treatment 
of sleep problems in individuals with intellectual disabilities. Furthermore, 
melatonin may result in the reduction of daytime challenging behaviour in this 
target group. Melatonin is also an effective treatment option for sleep problems in 
individuals with Angelman syndrome, a genetic cause of intellectual disability. 
Finally, we present a hypothesis on a not yet well-understood phenomenon of 
melatonin treatment: its disappearing effectiveness after several weeks. We 
suggest that this might be caused by slow melatonin metabolization, possibly due 
to dysfunction of the CYP1A2 gene. 
Meta-analysis
Our meta-analysis on the efficacy of exogenous melatonin for sleep problems in 
individuals with intellectual disability (see chapter 2) represents the first analysis 
on the efficacy of melatonin treatment of chronic insomnia in this target group. 
We found melatonin to be effective in reducing sleep latency, increasing total 
sleep time, and reducing the number of waking per night. these findings are in 
line with the outcome of our clinical studies, but in stark contrast to outcomes 
of three meta-analyses on the efficacy of exogenous melatonin in predominantly 
persons without intellectual disability (Brzezinski et al. 2005; Buscemi et al. 2005; 
Buscemi et al. 2006). We criticized several aspects of these three meta-analyses 
and discussed possible explanations for the discrepancies between the outcomes 
of our meta-analysis and those of the other three meta-analyses. First, in most 
studies in these three meta-analyses data were collected within a cross-over design 
which results in less favorable results in studies with melatonin. Secondly, many 
of these studies were performed in a sleep laboratory using polysomnography, 
resulting in smaller therapeutical results than in trials that were performed 
under home conditions. And thirdly, several studies were performed on healthy 
volunteers without sleep problems. this means that several included studies did 
not qualify for inclusion in a meta-analysis on the efficacy of melatonin in the 
treatment of chronic insomnia.
Results of the three meta-analyses in predominantly persons without 
intellectual disability were largely influenced by the inclusion criteria and the 
design and measurement methods of the included studies. Based on these meta-
analyses the Dutch insurance companies do not reimburse costs of melatonin 
treatment, because they state that the efficacy of melatonin as to improvement 
of sleep has up to now not been convincingly demonstrated. Our meta-analysis 
indicates that this decision was based on the outcome of studies whose methodology 
was flawed. Moreover, this decision of the Dutch insurance companies may 
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encourage physicians to resort to the prescription of less effective drugs with 
greater risk of daytime sedation and other unwanted side effects. 
treatMent with Melatonin
Our conclusion that melatonin is effective in the treatment of sleep problems 
is also based on positive outcomes of our placebo controlled studies. In these 
intervention studies, we used a parallel study design, because a cross-over study 
design with intra-individual comparison of melatonin and placebo is inappropriate 
when evaluating the efficacy of melatonin. Exogenous melatonin can cause a 
phase shift advance of the endogenous melatonin rhythm and this effect can last 
for several days or weeks after melatonin is withdrawn. therefore, participants 
who receive melatonin in the first phase of the study may experience a carry-over 
effect of the melatonin phase into the placebo phase (Kunz et al. 2004; Laakso et 
al. 2007). By consequence, carry-over effects can result in a smaller difference in 
parameters between melatonin and placebo phases of the study, and therefore be 
responsible for not finding a statistically significant difference between melatonin 
and placebo. this was the main reason why we opted for a parallel study design 
for our three studies.
In the first study (see chapter 3), we found melatonin to be effective in 
shortening sleep latency and increasing total sleep time, as well as reducing the 
mean number and duration of night wakings. Melatonin treatment also resulted 
in an advance of endogenous melatonin onset (DLMO). this reflects the main 
effect of melatonin, being a chronobiotic drug (Wirz-Justice & Armstrong 1996). 
the improvement of sleep maintenance is an interesting finding, because it is 
not in line with results of studies in insomniac individuals without intellectual 
disability, and in whom sleep maintenance problems are reported not to be 
influenced by melatonin treatment. 
In the second study (see chapter 4) we found that melatonin was effective 
in reducing sleep problems in children with Angelman syndrome. We were 
unexpectedly confronted with the phenomenon that in some individuals the 
treatment effect disappeared after a few weeks of treatment. After a one week 
drug holiday, the efficacy of melatonin returned after resuming therapy with a 
substantially lower dose. In chapter 6 we have explored causes of this effect and 
generated hypotheses for this effect.
In the third study (see chapter 5) we found that melatonin treatment not only 
reduced sleep problems, but also reduced daytime challenging behaviour. this 
is the first blinded study that shows such an effect. the reduction in daytime 
challenging behaviour after effective treatment of sleep problems in persons with 
intellectual disability is generally assumed to be caused by the improvement of 
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sleep (i.e. increase of total sleep time and reduction of sleep latency). However, 
we found that the severity of challenging behaviour did not correlate with the 
severity of sleep problems at baseline, nor did we find significant correlations 
between changes in challenging behaviour and improvements in sleep at the end 
of the treatment period, except for a correlation between change in challenging 
behaviour and change in the melatonin rhythm (DLMO) and the number of 
nights with wakings per week, respectively. It is plausible that the reduction in 
daytime challenging behaviour is not only caused by the improvement of sleep 
(e.g. increase in total sleep time), but also by the correction of a disturbed circadian 
melatonin rhythm as a second variable. this hypothesis needs to be evaluated in 
further studies. 
loss of response to exogenous Melatonin
In our pilot study on the loss of response to melatonin after an initial successful 
therapy (see chapter 6) we hypothesized that the decline in effectiveness 
was caused by extremely high melatonin levels, and that this was caused by a 
disturbance in melatonin metabolism due to a decreased activity / inducibility of 
CYP1A2. We found daytime salivary melatonin levels to be abnormally high after 
several weeks of melatonin treatment. the melatonin clearance test showed at 
least five hours lasting high melatonin levels after one single dose of melatonin, 
suggesting slow metabolization of melatonin.
Slow metabolization of melatonin results after a short treatment period (2 – 6 
weeks) with melatonin in 24-hour lasting high melatonin levels. Consequently 
the normal biphasic circadian melatonin rhythm disappears. Another explanation 
could be that exogenous melatonin might spill over onto the wrong zone of the 
melatonin phase response curve, as was suggested by Lewy et al. (2002). they 
were unable to entrain one out of seven totally blind people with free-running 
endogenous melatonin rhythms to 10 mg of exogenous melatonin. they found 
that this person could be entrained to 0.5 mg of melatonin, but not to 20 mg. this 
person had the longest circadian period (24.9 h) of the group. Subsequently Lewy 
et al. suggested that too much melatonin may spill over onto the wrong zone of 
the melatonin phase-response curve.
If melatonin should induce sleep pharmacologically, like benzodiazepine 
hypnotics do, these high serum melatonin levels would result in prolonged sleep, 
instead of poor sleep maintenance and early waking. this shows that melatonin is 
not just a hypnotic, but mainly a chronobiotic drug. Melatonin acts as a regulating 
switch, shifting the circadian phase (sleep-wake cycle) forward or backward, 
depending on the time when melatonin is taken (melatonin administered 5-6 
hours before Dim Light Melatonin Onset (DLMO) advances the melatonin rhythm 
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and its associated sleep-wake rhythm maximally, while melatonin delays these 
rhythms maximally, if administered 10 hours after DLMO). therefore, increased 
melatonin levels at both morning and evening hours can induce opposite circadian 
shifts and disturb the sleep-wake cycle. 
clinical iMplications 
First, we have evidently shown that melatonin is effective in treating chronic 
insomnia in persons with intellectual disability. Furthermore melatonin did 
improve co-morbid challenging behaviour. Secondly we found that in some cases 
the efficacy of melatonin treatment can disappear after a short period of treatment, 
probably because of slow metabolization, possibly by the CYP1A2 enzyme. 
Melatonin, however, is not just a hypnotic drug. Melatonin is a chronobiotic 
drug, influencing circadian biological clock rhythm, and has only slight soporific 
properties. these findings have consequences for prescription of melatonin by 
physicians, because they should be aware of the complicated pharmacokinetics 
for appropriate evaluation of the effectiveness of melatonin therapy. As long as 
melatonin is a non-licensed drug, melatonin therapy should be initiated and 
initially be controlled by physicians experienced in the treatment with this 
chronobiotic drug (with some slight hypnotic properties). this way only we can 
extend effectively our knowledge, and prevent negative experiences and resulting 
prejudices in physicians and policy makers. 
the melatonin dose needs to be substantially lower in individuals who are 
CYP1A2 poor metabolizer, in order to prevent high melatonin levels. to identify 
CYP1A2 poor metabolizers prior to melatonin treatment, a melatonin clearance 
test has to be performed. this test could consist of collecting saliva at 10:00 am, 
immediately followed by intake of melatonin (1mg, 0.5 mg or 0.1 mg, depending 
on age). Subsequently, saliva samples for melatonin measurements are collected 
at noon, 2:00 pm, 4:00 pm, and 08:00 am the next morning. Further studies 
should deal with the question whether the melatonin clearance test is a valid tool 
to determine at what dose melatonin should be prescribed, or that for this purpose 
CYP1A2 genotyping is necessary. Further studies are also needed to determine if 
CYP1A2 poor metabolizers have a higher incidence of (specific) sleep problems, 
are more prevalent in specific genetic syndromes, and can be recognized by more 
simple tests than a clearance test. We are aware that the clearance test often is 
not possible for practical reasons. In that case it is important to recognize the 
symptoms of the emergence of high melatonin levels, i.e. the return of sleep 
problems after an initial successful treatment effect.
Several patients treated in our sleep centre, that are CYP1A2 poor metabolizer, 
do not respond well to melatonin treatment in a substantially lower dose. We 
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are studying now the question if these patients respond better if omeprazole is 
prescribed next to the melatonin. the reason is that omeprazole has been shown 
to induce CYP1A2 activity (Rost & Roots 1994). 
Finally, the following advices can be given:
• Melatonin is indicated for the treatment of chronic sleep problems, 
due to a circadian rhythm sleep disorder occurring (almost) daily, that 
does not respond to sleep hygiene measures, strengthening time cues 
(zeitgebers) and adequately timed bright light treatment. Melatonin has to 
be prescribed preferably after measurement of evening melatonin levels 
to assess DLMO. 
• Administration of melatonin without measuring DLMO may cause 
a doctor’s delay of at least 3 months in patients who do not respond 
adequately on melatonin treatment, because it may last at least 3 months 
after stopping melatonin treatment, before the pretreatment endogenous 
melatonin rhythm is reached and a precise circadian rhythm sleep disorder 
can yet be diagnosed. 
• In patients with late dim light melatonin onset (DLMO) time of intake 
of melatonin should be 5 hours prior to time of DLMO but usually not 
earlier than 6 pm. In some exceptional cases melatonin administered 1 
hour before sleep onset might improve sleep maintenance. 
• Melatonin dose should be the lowest possible effective dose. 
• In case sleep problems return after an initial successful therapy, poor 
metabolizing of melatonin should be considered among other causes, 
such as inappropriate time of intake, intercurrent somatic or psychiatric 
disorders etc. In case of suspected slow metabolization of melatonin, 
melatonin day-time levels could be measured. In case poor metabolizing 
of melatonin is diagnosed, melatonin treatment effect usually returns 
when melatonin treatment is stopped during 1 tot 2 weeks and melatonin 
treatment is started again in a dose of about 20% of the prior given 
dose.
final reMark 
Melatonin is effective in reducing sleep problems in persons with intellectual 
disability. It should be considered an evidence-based treatment option for sleep 
problems in this target group. While it is effective for most individuals, it may 
however lose its effectiveness in some individuals. In this thesis we have presented 
a hypothesis on the cause of the disappearing effect of melatonin and provided 
clinical guideline how to approach this. 
DISCUSSION
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suMMary
background
Results of several studies suggested that melatonin may be effective in the treatment 
of sleep problems in individuals with intellectual disability and chronic insomnia. 
Its efficacy in these individuals, however, had not been firmly and unequivocally 
established. Furthermore, it remained unclear whether challenging behaviour 
reduced as a result of successful treatment of sleep problems with melatonin.
In some individuals, effectiveness of melatonin decreased several weeks 
after melatonin treatment had started. In these cases, effectiveness of melatonin 
returned following substantial reduction in dosage. It was unclear what may 
account for this wearing-off effect of melatonin.
to investigate efficacy of melatonin in individuals with intellectual disability 
who have sleep problems, to assess influence of melatonin treatment of challenging 
behaviour and to generate hypotheses about the cause of the wearing-off effect of 
melatonin we performed the studies described below.
studies on Melatonin
Results of a meta-analysis of the effectiveness of melatonin for sleep problems in 
individuals with intellectual disabilities are reported in chapter 2. Nine placebo-
controlled randomized studies were included that were published between 1990 
and 2008. Analyses revealed that melatonin treatment significantly decreased 
sleep latency by a mean of 34 minutes, increased total sleep time by a mean of 50 
minutes, and decreased the number of wakings per night. 
In chapter 3, effectiveness of melatonin for sleep problems was assessed 
within a randomized double-blind placebo-controlled study. Participants were 51 
individuals with intellectual disabilities who presented with chronic idiopathic 
sleep problems for more than one year. Data on several sleep parameters were 
collected during a 1-week baseline and after 4 weeks of treatment. Endogenous 
dim light melatonin onset (DLMO) was measured in saliva before and after 
treatment. After a 1-week baseline, participants were given either melatonin 5 
or 2.5 mg (depending on age) or placebo. Results showed that compared with 
placebo, melatonin significantly advanced mean sleep onset time by 34 minutes, 
decreased mean sleep latency by 29 minutes, increased mean total sleep time by 
48 minutes, reduced the mean number of night-time waking and advanced DLMO 
by an average of 2 hours. Lights off time, sleep offset time and the number of 
nights per week with night waking did not change. Only few minor or temporary 
adverse reactions and no changes in seizure frequency were reported. 
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this study was replicated in 8 children with Angelman syndrome who had 
idiopathic chronic insomnia (chapter 4). Data were also collected in a randomized 
placebo-controlled double-blind study. Results showed that on average melatonin 
significantly advanced sleep onset by 28 minutes, decreased sleep latency by 
32 minutes, increased total sleep time by 56 minutes, reduced the number of 
nights with wakings from 3.1 to 1.6 nights a week, and increased endogenous 
salivary melatonin levels. It was noteworthy that in 3 of the 4 children who 
received melatonin, salivary melatonin levels were extremely high after 4 weeks 
of treatment and their parents reported the return or increase of night wakings. 
After reducing the dosage sleep problems were reduced.
In chapter 5, we investigated effects of melatonin on challenging behaviour 
using data from trials reported in chapter 2 and 3. Participants were 49 individuals 
with intellectual disabilities who had a mean age of 18 years and who had chronic 
insomnia. they received either melatonin 5 mg (<6 years 2.5 mg) or placebo 
for 4 weeks. Daytime challenging behaviour was measured by the Storend 
Gedragsschaal voor Zwakzinnigen at baseline week and the end of the fourth 
treatment week. Salivary dim light melatonin onset (DLMO) was measured at 
baseline and the last day of the fourth treatment week. Sleep logs were used to 
gather information on sleep parameters. Results showed that on average melatonin 
treatment significantly reduced SGZ scores, sleep latency, and number and 
duration of night wakings, and increased total sleep time and advanced DMLO. 
Strong correlations were found between change in SGZ scores, change in DLMO 
and number of night wakings. these results indicate that melatonin treatment 
in persons with intellectual disabilities and chronic insomnia decreased daytime 
challenging behaviour probably by improving sleep maintenance or by improving 
circadian melatonin rhythmicity.
Initial good response to melatonin in some participants disappeared within a 
few weeks after starting melatonin treatment, while the good response returned 
only after considerable dose reduction. In a pilot study (chapter 6) we measured 
metabolism of melatonin in two female (aged 61 and 6 yr.) and one male (aged 
3 yr.) patient with mild intellectual disability. they had chronic insomnia and a 
late melatonin onset. their sleep quality had worsened a few weeks after initial 
good response to melatonin treatment. this suggested melatonin tolerance. 
After a 3 week washout period, these patients received melatonin 1.0, 0.5 or 0.1 
mg respectively. Salivary melatonin level was measured just before melatonin 
administration, and 2, 4 and 6 hours thereafter. After the melatonin clearance 
test, melatonin treatment was resumed with a considerably lower dose. In all 
patients melatonin concentrations remained >50 pg/ml at 2, 4 and 6 hours after 
melatonin administration. After resuming melatonin treatment sleep problems 
disappeared. the same procedure was followed in 3 patients who did not show a loss 
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of response to melatonin treatment. In all patients in the control group melatonin 
concentrations decreased between 2 and 4 hours after melatonin administration 
with a mean decrease of 76%. We hypothesize that loss of response to melatonin 
treatment is caused by slow metabolism of exogenous melatonin, probably due to 
decreased activity/inducibility of CYP1A2.
general conclusion
Our studies show that melatonin improves sleep (i.e. reduces severe sleep problems) 
and daytime behaviour (i.e., reduced challenging behaviour) in individuals with 
intellectual disabilities (including those with Angelman syndrome) and chronic 
insomnia. the wearing-off phenomenon of melatonin treatment in some cases 
might be caused by slow metabolism of melatonin, possibly associated with 
dysfunction of the CYP1A2 gene.
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saMenvatting
achtergrond
Uit diverse studies blijkt dat melatonine effectief kan zijn bij de behandeling van 
slaap problemen bij mensen met een verstandelijke beperking. De effectiviteit 
bij deze groep mensen is echter tot nu toe niet duidelijk en ondubbelzinnig 
aangetoond. Daarnaast is niet duidelijk vastgesteld of gedragsproblemen bij 
mensen met een verstandelijke beperking die slaapproblemen hebben, afnemen 
wanneer deze slaapproblemen met succes worden behandeld met melatonine.
Bij sommige mensen met een verstandelijke beperking die met melatonine 
worden behandeld, neemt na enkele weken succesvolle behandeling de effectiviteit 
van melatonine af. Het was tot nu toe niet bekend wat de oorzaak is van de afname 
van de werking van melatonine.
Om bij mensen met een verstandelijke beperking en slaap problemen 
de werkzaamheid van melatonine en de invloed op storend gedrag overdag te 
onderzoeken, en om een hypothese te vormen over de oorzaak van het afnemend 
effect van melatonine bij sommige gebruikers, voerden we de hieronder vermelde 
studies uit. 
studies Met Melatonine
De resultaten van een meta-analyse naar de werkzaamheid van melatonine bij de 
behandeling van slaapproblemen bij personen met een verstandelijke handicap, 
worden gerapporteerd in hoofdstuk 2. In deze analyse werden 9 placebo-
gecontroleerde gerandomiseerde studies, gepubliceerd tussen 1990 en 2008, 
opgenomen. Uit de analyses bleek dat de behandeling met melatonine leidde 
tot een aanzienlijke afname van de inslaaplatentie met een gemiddelde van 34 
minuten, toename van de totale slaaptijd met een gemiddelde van 50 minuten en 
een daling van het aantal malen wakker worden per nacht.
De resultaten van een gerandomiseerd dubbelblind placebo-gecontroleerde 
studie naar de effectiviteit van melatonine bij slaapproblemen, worden gemeld 
in hoofdstuk 3. Dit onderzoek werd uitgevoerd bij 51 personen met een 
verstandelijke beperking, die onze polikliniek bezochten wegens meer dan een 
jaar bestaande chronische slaapproblemen. Deelnemers kregen ofwel melatonine 
5mg (2,5 mg <6jr), dan wel een placebo. Gegevens over de verschillende slaap 
variabelen werden verzameld tijdens de basisweek en tijdens de 4 weken durende 
behandeling. Melatonine spiegels werden gemeten in speeksel aan het eind van 
de basis week en aan het einde van de vierde behandelweek. 
De resultaten toonden aan dat, in vergelijking met placebo, melatonine het 
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tijdstip van in slaap vallen gemiddeld met 34 minuten significant vervroegde, 
de gemiddelde slaaplatentie met 29 minuten verkortte, de gemiddelde totale 
slaaptijd met 48 minuten verlengde, het aantal malen ‘s nachts wakker worden 
verminderde en de DLMO (Dim Light Melatonin Onset: het tijdstip waarop 
’s avonds de stijging van de melatonine spiegel aanvangt) met gemiddeld 2 uur 
vervroegde. Het tijdstip van ‘s avonds licht uit doen, ‘s morgens wakker worden 
en het aantal nachten per week met ‘s nachts wakker worden, veranderde niet 
significant. Er werden slechts enkele milde of tijdelijke bijwerkingen en geen 
veranderingen in de frequentie van epileptische aanvallen gemeld.
Deze studie werd met dezelfde opzet herhaald bij 8 kinderen met het 
Angelman syndroom en chronische slapeloosheid (hoofdstuk 4). De resultaten 
toonden aan dat melatonine het tijdstip van in slaap vallen gemiddeld met 28 
minuten significant vervroegde, de inslaaplatentie met gemiddeld 32 minuten 
verkortte, de gemiddelde totale slaaptijd met 56 minuten verlengde, het aantal 
malen ‘s nachts wakker worden van gemiddeld 3,1 tot 1,6 nachten per week deed 
afnemen en de endogene melatonine spiegels, gemeten in speeksel, verhoogde. 
Het was opmerkelijk dat bij 3 van de 4 kinderen die melatonine kregen, de 
melatonine spiegels in speeksel na 4 weken behandeling extreem hoog bleken 
te zijn en hun ouders de terugkeer of toename van het ‘s nachts wakker worden 
meldden. Na sterke verlaging van de dosering namen deze slaap problemen 
weer af. 
In hoofdstuk 5 onderzochten we de gevolgen van een behandeling met 
melatonine op storend gedrag met behulp van gegevens uit de twee studies die 
werden gerapporteerd in hoofdstuk 2 en 3. De deelnemers waren 49 personen met 
een verstandelijke beperking en chronische slapeloosheid. De gemiddelde leeftijd 
was 18 jaar. Ze kregen ofwel 5 mg melatonine (<6 jaar 2,5 mg) of een placebo 
gedurende 4 weken. Storend gedrag werd gemeten door invullen van de Storend 
Gedragsschaal voor Zwakzinnigen tijdens de basisweek en aan het einde van de 
vierde behandel week. Het moment van aanvang van de melatonine afgifte (DLMO) 
werd gemeten aan het eind van de basisweek en de vierde behandelweek. Een 
slaap dagboek werd gebruikt om informatie te verzamelen over slaap variabelen. 
De resultaten toonden aan dat de behandeling met melatonine de SGZ scores, 
de inslaap latentie en het aantal en de duur van het nachtelijk wakker worden, 
aanzienlijk verminderde, de totale slaaptijd verlengde en de DLMO vervroegde. 
Sterke correlaties werden gevonden tussen de veranderingen in de SGZ scores en 
de verandering in de DLMO en het aantal malen nachtelijk wakker worden. Deze 
resultaten geven aan dat een behandeling met melatonine bij personen met een 
verstandelijke beperking en chronische slapeloosheid het storend gedrag overdag 
vermindert, waarschijnlijk door een verbetering van de slaap, en/of door een 
verbetering van het circadiane melatonine ritme.
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Een aanvankelijk goede respons op een behandeling met melatonine kan bij 
sommige patiënten binnen een paar weken na het starten van de behandeling 
verdwijnen, terwijl de goede respons pas terugkeert na een aanzienlijke verlaging 
van de dosis. In onze pilot studie (hoofdstuk 6) hebben we de metabolisatie van 
melatonine gemeten bij twee vrouwelijke patiënten (leeftijd 61 en 6 jaar) en een 
mannelijke patiënt (leeftijd 3 jaar), met een matige verstandelijke beperking. Er 
was sprake van chronische slapeloosheid en een laat begin van de melatonine 
afgifte. Bij hen verslechterde de slaap een paar weken na een aanvankelijk 
goede respons op een behandeling met melatonine, wat zou kunnen wijzen op 
melatonine tolerantie. Na een wash-out periode van 3 weken kregen de patiënten 
‘s morgens respectievelijk 1,0, 0,5 of 0,1 mg melatonine. Speeksel melatonine 
spiegels werden gemeten nét voor melatonine toediening, en 2 en 4 uur daarna. 
Na de melatonine clearance test werd de behandeling hervat met een aanzienlijk 
lagere dosis melatonine.
Bij alle patiënten bleven de melatonine spiegels 2 en 4 uur na toediening 
van melatonine > 50 pg/ml. Na hervatting van de behandeling met melatonine 
verdwenen de slaapproblemen. Dezelfde procedure werd gevolgd bij 3 patiënten 
bij wie geen sprake was van een afnemend effect van melatonine na 6 maanden 
gebruik. Bij alle patiënten in de controle groep vertoonden de melatonine spiegels, 
afgenomen tussen 2 en 4 uur na toediening van melatonine, een gemiddelde 
afname van 76%. Onze hypothese is dat het afnemend effect van melatonine wordt 
veroorzaakt door langzame metabolisatie van exogeen melatonine, waarschijnlijk 
als gevolg van een verminderde activiteit / inducibility van CYP1A2, mogelijk als 
gevolg van een mutatie van het CYP1A2-gen.
slotconclusie
Onze studies tonen aan dat melatonine bij mensen met een verstandelijke 
beperking en chronische slaapproblemen zowel de slaap verbetert (dat wil zeggen 
slaapproblemen vermindert) als het gedrag overdag verbetert (dat wil zeggen het 
overdag storend gedrag doet afnemen). Het fenomeen van de afnemende melatonine 
effectiviteit bij sommige patiënten kan worden veroorzaakt door langzame 
metabolisatie van melatonine, waarschijnlijk veroorzaakt door een mutatie in het 
CYP1A2 gen.
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